Abstract
Atherosclerosis (AT) is a progressive chronic disease involving lipid accumulation, fibrosis, and inflammation in medium and large-sized arteries, and it is the main cause of cardiovascular disease (CVD). AT is caused by dyslipidemia and mediated by both innate and adaptive immune responses. Despite lipid-lowering drugs have shown to decrease the risk of cardiovascular events (CVEs), there is a significant burden of AT-related morbidity and mortality. Identification of subjects at increased risk for CVE as well as discovery of novel therapeutic targets for improved treatment strategies are still unmet clinical needs in CVD. Microvesicles (MVs), small extracellular plasma membrane particles shed by activated and apoptotic cells have been widely linked to the development of CVD. MVs from vascular and resident cells by facilitating exchange of biological information between neighboring cells serve as cellular effectors in the bloodstream and play a key role in all stages of disease progression. This article reviews the current knowledge on the role of MVs in AT and CVD. Attention is focused on novel aspects of MV-mediated regulatory mechanisms from endothelial dysfunction, vascular wall inflammation, oxidative stress, and apoptosis to coagulation and thrombosis in the progression and development of atherothrombosis. MV contribution to vascular remodeling is also discussed, with a particular emphasis on the effect of MVs on the crosstalk between endothelial cells and smooth muscle cells, and their role regulating the active process of AT-driven angiogenesis and neovascularization. This review also highlights the latest findings and main challenges on the potential prognostic, diagnostic, and therapeutic value of cell-derived MVs in CVD. In summary, MVs have emerged as new regulators of biological functions in atherothrombosis and might be instrumental in cardiovascular precision medicine; however, significant efforts are still needed to translate into clinics the latest findings on MV regulation and function.
Introduction
Despite significant advances in prevention, diagnosis, and therapeutic intervention focused on strategies for preventing cardiovascular disease (CVD), coronary artery disease (CAD) remains the leading cause of mortality and morbidity worldwide. Since not every individual has the same risk of developing future cardiovascular events (CVEs), an important challenge in cardiovascular medicine is to accurately predict who will develop atherosclerosis (AT)-related complications, such as acute coronary syndromes (ACS). Current tools to predict atherosclerotic vascular complications perform only poor to moderate. This emphasizes that there is an unmet need for novel biomarkers to stratify the risk of atherosclerotic complications in the intermediate and high-risk population on top of classical risk factors.
Atherosclerosis, the hallmark sign of CVD, is a silent hypercholesterolemia-triggered chronic systemic inflammatory process of the artery wall that is characterized by deposition of lipids within the intima of elastic arteries. This leads to structural damage and formation of fatty streaks with subsequent loss of elasticity, which can develop to fiber and atheromatous plaques, resulting in thrombus formation and narrowing of the luminal. Damage to arterial endothelial cells (ECs) is considered the earliest event in atherogenesis. Development of atherosclerotic plaques also includes the continuous crosstalk between EC, smooth muscle cells (SMCs), inflammatory cells, and inflammatory mediators (1) acting through mechanisms that have not yet been completely revealed.
Microvesicles (MVs), with a diameter ranging from 0.10 to 1.00 μm, are small plasma membrane vesicle fragments, also known as microparticles (MPs), that are released by many cell types, such as platelets, leukocytes, ECs, erythrocytes, and SMCs, into different bodily fluids, including plasma, urine, saliva, milk, sweat, semen, and tears, as well as in conditioned media from cell culture experiments (2, 3) (Figure 1). Depending on the generation mechanism, there are distinct types of extracellular vesicles, including MVs, apoptotic bodies, and exosomes (4), being MVs the most heterogeneous and studied population so far. The present review particularly focuses on MVs, which are specifically formed by budding of the plasma membrane, a releasing process that is driven by calcium-dependent signaling, activity of several enzymes, cytoskeleton remodeling, and externalization of phosphatidylserine (PS). MVs are shed under basal conditions and their release increases with various stimuli and pathological settings. In contrast to MVs, apoptotic bodies are larger permeable membrane vesicles with a diameter >1 μm containing apoptotic nuclear material while exosomes constitute the smallest extracellular vesicle type (ranging from 40 to 100 nm in diameter), highly enriched in lipids and tetraspanins, and actively shed from intracellular multivesicular bodies upon fusion with the cell membrane.
Figure 1
Microvesicles are specifically composed of lipids, genetic material, such as mRNA, non-coding ribonucleic acids (RNAs) [microRNA (miRNA)], or even small amounts of DNA, and proteins such as transcription factors, cytokines, and growth factors (Figure 1). Interestingly, the packaging of distinct biomolecules into MVs seems to occur in a non-randomly fashion. Thus, specific miRNAs were seen to be preferentially sorted into MVs. Blood cells and cultured monocytic THP1 cells actively and selectively secreted MV-loaded miRNAs into the circulation in response to various stimuli (5). Nevertheless, further efforts are needed toward a complete understanding of this regulated sorting mechanism. MVs have been characteristically recognized by the externalization of PS on the outer membrane leaflet. However, this property has recently been a matter of debate. New evidence suggests that some MVs can express cell markers without annexin V binding (6, 7). Interestingly, MVs harbor on their surface transmembrane and receptor proteins from the parental cells from which they derived from. This property, important for specific cell–cell interactions, is also used in MV identification and characterization by high-sensitivity flow cytometry. MVs can deliver their cargo to cells nearby or in remote locations, perpetuating the intercellular communication process. Since their content fluctuates depending on the pathological context, MVs have drawn the attention as a potential source of biomarkers for disease identification (8).
Flow cytometry has been the gold standard methodological choice for MV measurements. Recently, some new methods (9) such as atomic force microscopy have been developed. Today there is still a general need of establishing preanalytical steps for MV isolation and of validating novel techniques. Recent efforts (10–12) are addressed to standardize MV analytical procedures between instruments and laboratories (13).
Microvesicles promote the development and progression of AT, by inducing endothelial dysfunction (ED) and initial lesion formation, influencing cell communication, promoting inflammatory reactions and participation in lipid deposition, neovascularization, calcification and unstable plaque progression, and injured plaque clotting and thrombosis after rupture. Here, we review the current and last data on the role of MVs in AT and CVD, highlighting their relevance for vascular remodeling and neovascularization. In addition, we discuss the emerging interest of MVs as prognostic and diagnostic biomarkers of disease and their potential use as therapeutic agents.
MV-Mediated Regulatory Mechanisms in the Development and Progression of AT
Several evidences support a direct functional role for circulating MVs in atherothrombosis. They span from the early stages related to the presence of classical cardiovascular risk factors (CVRF) (e.g., hyperlipidemia, diabetes, and hypertension) to acute cardiovascular and cerebrovascular events as result of their effect on intercellular communication processes transferring proteins, non-coding RNAs, and even mRNAs (14) to target cells. Specifically, MVs are able to (1) fuse with plasma membrane of target cells and transfer their cargo into the recipient cells, (2) interact with target cells via a receptor-mediated signaling mechanism, and (3) be internalized via endocytosis and fused with either endosomes to release their content into the cytosol or lysosomes to be degraded (2). To bridge the gap between atherosclerotic lesion initiation, plaque rupture, and CVEs, multifaceted MV-driven molecular mechanisms of AT progression linked to endothelial homeostasis, inflammation, and thrombosis will be discussed.
Endothelial Dysfunction
Endothelial cells exert natural barrier functions in the vessel wall to prevent pathogen invasion and to maintain vascular integrity, through the balanced release of cell and molecular components acting at paracrine and autocrine level. Vascular ECs change their phenotype and function in response to mechanical injury and systemic factors, such as dyslipidemia, smoking, and other stimuli and/or risk factors.
Recent studies support a direct relationship between the levels of circulating endothelial-derived MVs (eMVs) and the degree of ED in patients with end-stage renal failure (15), congenital heart disease (16), CAD (17, 18), type 2 diabetes (T2D) (19), and obesity and hypertension (20). Indeed, MVs are able to interact with the vascular endothelium and promote cellular dysfunction (Figure 2). Thus, MVs from T2D patients have shown to attenuate eNOS expression in cultured EC (21). Furthermore, MVs of endothelial origin have shown to decrease nitric oxide (NO) production in vitro (22, 23) and under high glucose conditions through changes in oxidative stress (24) or inducing a temporal cross talk between mitochondria and endoplasmic reticulum (25). These effects have been obtained in ex vivo studies (23, 26) and with patient-derived MVs in pathologies such as myocardial infarction (MI) (27), end-stage renal failure (15), metabolic syndrome (28), valvular heart disease and cardiac injury (29), and undergoing percutaneous coronary intervention (30). As a result, vascular tone and endothelial repair capacity are altered. Studies in vitro using rat aortic rings provided evidence that eMVs lead to impaired acetylcholine-mediated vasorelaxation (22), and studies ex vivo with eMVs from ACS patients induced premature ED, senescence, and thrombogenicity through an angiotensin II-dependent redox activation of phosphoinositide 3-kinase/Akt and mitogen-activated protein kinases pathways (31). In addition, when MVs obtained from plasma of subjects with metabolic syndrome, were injected intravenously in mice, a severe impairment of endothelium-triggered vasorelaxation with decreased NO-synthase expression was detected (28). Horn et al. reported that MVs carry functionally active NO synthase that induce NO production within the MVs, a function downregulated in MVs from patients with ED (32). These results indicate that eMVs have a functional role in the control of vascular homeostasis.
Figure 2
The physiopathological conditions stimulating MVs formation have an impact on MV phenotype and functional activity. Interestingly, Mahmoud and colleagues reported that MVs from healthy individuals or shed under basal conditions had no effects on endothelial function, while in vitro generated eMVs exert a protective role on endothelial function in a free-fatty acid-induced model, via eNOS/Akt signaling and reduced oxidative stress (33). This recent study reflects on how MVs may behave as different biological effectors in health and disease, highlighting the relevance of the environment and pathological stimuli triggering MV release on their phenotype and biological activity.
Injured endothelium beyond promoting the recruitment of activated platelets to repair damaged ECs, also facilitates adherence of platelet-derived MVs (pMVs) to the vascular wall (Figure 2), inducing in turn the permeability and apoptosis of ECs, the latter by MV transfer of caspase-3 and Rho-kinase enzymes according to the in vitro findings reported by Edrissi et al. (34). More specifically, these authors have proved that plasma-derived MVs from rats submitted to chronic cerebral ischemia contain factors involved in the activation of the tumor necrosis factor (TNF)-α pathway that delivered to ECs regulate endothelial permeability in vitro.
Vascular Wall Atheroinflammation
The role of MVs on the propagation of endothelial proinflammatory response was initially reported in in vitro studies showing that blood-derived MVs (obtained from either plasma and/or cell cultures, and also induced by high-shear stress) raise the release of cytokines and cell adhesion molecules in ECs (35, 36) and in leukocytes (37). In addition, circulating MVs obtained from healthy volunteers after infusion of a chemotactic peptide induced cytokine and chemokine release in in vitro EC cultures (38). Similar findings have been reported using MVs from both animal models and patients (39, 40). Thus, MVs obtained from a high-fat diet-fed obese murine model of insulin resistance and T2D induced the expression of vascular cell adhesion molecule-1 and reactive oxygen species (ROS) production in rat cardiac ECs (41). Furthermore, MVs have also shown to increase the monocyte expression of cell surface antigens such as CD11a/CD18 and CD11b/CD18 αM/β2 (37) and the endothelial expression of intercellular cell adhesion molecule-1 (ICAM-1) (42, 43). Increasing evidences suggest that regulation of protein expression by MVs is dependent on their miRNA-cargo. Thus, MV-mediated regulation of ICAM-1 expression in ECs is dependent on their content in miRNA-222 and its transfer to the target cells (44). MV-associated inflammatory cascade promotes the binding of monocytes to the endothelium and their infiltration into the atherosclerotic plaque (Figure 2) (24, 37, 45–47). Indeed, in vitro studies demonstrated that monocyte and leukocyte activation and adhesion is regulated by eMVs transferring miRNA-10 to the monocyte and thereby targeting nuclear factor-κB inflammatory pathway (48) and by MVs that carry arachidonic acid as well as oxidize phospholipids (45). Another smart study showed that pMVs transfer proatherogenic C–C motif chemokine 5 [regulated on activation, normal T cell expressed and secreted (RANTES)] to either activated ECs or murine atherosclerotic carotid arteries enabling monocyte adherence (46). Thus, MVs might contribute to the early atherosclerotic lesions development by promoting leukocyte adhesion to the endothelium.
Oxidative Stress, Apoptosis, and Vascular Remodeling
The seminal study of Forlow et al. showed that pMVs expressing P-selectin (P-Sel) promoted monocyte infiltration by facilitating leukocyte–leukocyte interactions under detrimental flow conditions (Figure 2) (49). Besides, lipid-containing MVs derived from various cell types promote foam cell formation and programmed cell death by inducing lipid and cholesterol accumulation in macrophages through a toll-like receptor induced mechanism in vitro and in a human skin model (50). TNF-α-induced eMVs contributed to apoptosis and inflammation of ECs in vitro (51). Delivery of the proapoptotic enzymes caspase-1 and caspase-3 to target cells by eMVs, pMVs, monocyte-derived MVs (mMVs), T-lymphocyte-derived MVs (ℓMVs), and erythrocyte-derived MVs trigger macrophage cell apoptosis in vitro (52–56), which in turn causes more MV release, amplifying the process and facilitating progression of the atherosclerotic lesion. Thus, human atherosclerotic lesions contain MVs (57, 58) being those of monocyte and macrophage origin the most abundant. Apoptosis cell-derived MVs amplify the initiation and maintenance of inflammation in human monocytes together with interferon γ (59) in contrast to a recent study pointing out that MVs released from apoptotic cells provoke less inflammatory response than MVs from viable cells in monocytes, relating this effect with the specific miRNAs pattern found in these MVs (60). Furthermore, atherogenic low-density lipoprotein (LDL) modified by aggregation induce the release MVs enriched in tissue factor (TF) from SMCs (61) (Figures 2 and 3). pMVs increased SMC proliferation (62) by a mechanism independent of platelet-derived growth factor (PDGF) (63) whereas mMVs induced SMC death by caspase-1 (56).
High-risk plaques have a large lipid content covered by a thin fibrous cap penetrated by proinflammatory cells and a diffuse pattern of calcification (64, 65). The level of calcification has associated either with plaque burden (66) and lesion destabilization (67) or with less prone to rupture plaques (68). It seems plausible that the effect of calcification on atherosclerotic lesions evolves from a destabilizing effect in early lesions to a potential stabilizing effect of larger calcium burden in more advanced plaques (69). MVs from ECs, VSMCs, and macrophages seem to be recruited at the site of atherosclerotic plaque calcification and have been associated with the calcification process (70–73). Regarding MV-associated modulation of fibrous cap weakening, several cell-derived MVs can influence the progressive depletion of VSMCs and extracellular matrix degradation through metalloprotease interaction. Specifically, the involved molecular effectors are matrix metalloproteinase 9 (MMP-9), a disintegrin and metalloprotease-10 (ADAM-10) and -17 (ADAM-17) in neutrophil-derived MVs [(74, 75), respectively], MMP-9, matrix metalloproteinase-2 (MMP-2), and MMP-10 in eMVs [(76–78), respectively], and the metalloprotease TNF-α converting enzyme (TACE/ADAM-17) of human atherosclerotic plaques-derived MVs (79). A relevant finding is that the shedding of matrix MVs from arterial intimal SMCs was found higher in athero-prone areas of the human aorta than in athero-resistant areas at the preatherosclerotic disease stage with quantitative electron microscopic analyses (80). Shear stress-induced eMVs-containing miRNA-143 and miRNA-145 prevented VSMC dedifferentiation (81). Likewise, circulating MVs bearing miRNA-223 could penetrate the vascular wall and inhibit VSMC proliferation and migration, resulting in a decreased plaque size (82).
Coagulation and Thrombosis
The potential role of MVs in atherothrombosis is supported by a large number of studies. Procoagulant MVs are located within human advance vulnerable plaques (83). Upon atherosclerotic plaque erosion or rupture, the high-risk vulnerable plaque exposes their vascular contents to the blood flow, the coagulation cascade is activated and, concomitantly, there is recruitment and activation of circulating platelets that may lead to thrombus formation. Thrombosis may compromise arterial blood flow supply leading to the presentation of oxygen deficiency and the presence of MI.
First described as platelet dust (84), MVs are procoagulant biological effectors due to the surface content of negatively charged PS, which confers them high binding capacity for coagulating factors, being prominently higher in MVs than cell surface membrane in the case of platelets (85). The presence of other molecules and receptors including TF (83), factor VIII and Va (86), P-selectin glycoprotein ligand-1 (PSGL-1) (87), glycoprotein IIb/IIIa (88), and protein disulfide isomerase (PDI) (89) on MV surface might further enhance clot formation and thrombosis. TF can be functionally transferred via MVs to monocytes and other cells (90, 91). Protease-activated receptor 2 activation favors the shedding of TF-rich MVs through a process involving filamin A. Specifically, the interaction of TF with filamin A translocate cell surface TF to cholesterol-rich lipid rafts, promoting its activity and release into MVs (92). Indeed, procoagulant TF-rich MVs are increased by hyperinsulinemia (93) and found increased in patients with T2D (94). Recently, it has been shown that proinflammatory cytokine IL-33 induces differential TF expression and activity in intermediate monocyte subset as well as the release of procoagulant MVs rich in TF (95), emphasizing the interplay between inflammation and thrombosis (Figure 3).
Figure 3
Several key studies have addressed how MVs affect the clotting process (Figure 3). Upon endothelial injury, pMVs can bind to subcellular matrix to enhance clotting (96). Noteworthy, we reported that circulating and platelet-derived MVs exert direct effects on atherothrombosis by promoting platelet and fibrin deposition on atherosclerotic arterial wall (97). We performed a proof-of-concept study by perfusing blood with and without exogenously added pMVs to injured atherosclerotic vessel wall and demonstrated that elevated levels of pMVs were able to enhance platelet and fibrin adhesion under conditions of high-shear stress (97, 98). Indeed, a decreased level of pMVs bearing surface epitopes of adhesion and activation was found in blood perfusing prothrombotic surfaces, and also in ST-segment elevation myocardial infarction (STEMI) patients (99), supporting the high tendency to adhere of pMVs (49). High-shear stress-induced pMVs induce enhanced expression of cell adhesion molecules in ECs and monocytes (36) and regulate monocytes involvement in AT and inflammation (37). Interestingly, MVs from healthy subjects support low-grade thrombin generation (100) and are able to activate a stress signaling pathway in ECs leading to increased procoagulant activity (35); and PDI-bearing pMVs promote platelet hyperaggregability and insulin degradation in patients with T2D (89). Furthermore, interactions between platelet P-selection with PSGL-1 of leukocyte-derived MVs (LMVs) are required to concentrate TF activity at the thrombus edge to promote thrombus formation (87). MVs carrying functional TF might enable the growth of unregulated thrombus generation and fibrin formation and thrombus propagation ultimately leading to thrombotic complications (101).
Potential Prognostic, Diagnostic, and Therapeutic Value of Cell-Derived MVs in AT
CV diseases reflect a continuum of mechanisms underlying the gradually progressing AT. In addition to the pathogenic effects of MVs in AT and thrombosis, circulating levels of MVs (cMVs) of different cellular origin are increased in CVDs and reflect the severity of the different stages of the pathophysiology (102), thus cMVs might serve as potential diagnosis and prognosis biomarkers, which would be valuable tools for cardiovascular risk prediction as well as for evaluating the pharmacological response to therapeutic interventions.
Circulating microvesicles exist in the blood of normal healthy individuals released upon activation and in some cases apoptosis of vascular cells. Indeed, MV levels show gender-specific differences (103, 104) and changes are observed with age (105), during pregnancy (106), after exercise (107–109) and after a high-fat meal (110). It is important to recognize that differences may arise depending on age, gender, body mass index, lipid, hormone levels, smoking status and other confounding variables in apparently healthy subjects when evaluating cMVs for pathogenic potential (111). Another relevant issue to bear in mind when studying cMVs is their clearance mechanism, which might influence the levels of cMVs and could also be impaired by CVRF.
Cardiovascular Risk Factors
The number and phenotype of cMVs has been associated to major CVRF, such as smoking, diabetes mellitus, obesity, hypertension, dyslipidemia, and metabolic syndrome (Table 1). Within hyperlipidemia, it has been shown that in patients with heterozygous familial hypercholesterolemia (FH), pMVs carrying TF identify subclinical atherosclerotic plaque burden (112), and ℓMPs are able to discriminate between lipid-rich and fibrous atherosclerotic plaques in the same patients (113), thus reflecting that chronic exposure to high levels of LDL activates the vascular compartment by distinct mechanisms. Therefore, CVRF correlate with increased numbers of MVs indicating that MVs might be active in triggering thrombosis and further contributing to an increased risk of CVEs.
Table 1
| CVRF and atherothrombotic diseases | Reference | |
|---|---|---|
| CVRF | Smoking | (114–116, 117) |
| DM | Insulin resistance (118) DM (119–123) Type 2 DM (124–127) DM with microvascular complications (128) | |
| Obesity | In children (129) In adults (114, 130, 131) Caloric restriction/bariatric surgery (132) | |
| Hypertension | (18, 133–135) | |
| Dyslipidemia | Dyslipidemia (112, 113, 126, 136) | |
| Metabolic syndrome | Clustering of CVRF (28, 137–139) Cardiometabolic risk (140) | |
| Uremia | (141) | |
| Atherosclerosis (AT) | FRS | (140, 142) |
| ED | (15, 115) | |
| Calcification | (143) | |
| PAD | (105, 144) | |
| Subclinical AT | (19, 112, 113, 145) | |
| Stable CAD | (17, 146–148) | |
| CVD | ACS | (142, 146, 149–154) STEMI (155, 156) |
| Cerebrovascular disease | Ischemic stroke (157–162) Cerebral vasospasm (163) Lacunar infarcts (157) Carotid AT (164) | |
Microvesicle-associated prognostic and diagnostic value in cardiovascular risk stratification and CVDs.
ACS, acute coronary syndromes; CAD, coronary artery disease; CVD, cardiovascular disease; CVRF, cardiovascular risk factors; DM, diabetes mellitus; ED, endothelial dysfunction; FRS, Framingham Risk Score; PAD, peripheral artery disease; STEMI, ST-segment elevation myocardial infarction.
Atherosclerosis
Several studies have shown an association between cMVs and the Framingham Risk Score (used to predict CVD risk), ED, coronary calcification, peripheral artery disease, and subclinical AT (Table 1). Our group has recently reported that subjects at high cardiovascular risk who were about to develop a major CVE have increased levels of blood CD3+/CD45+ cMV (165). This is in agreement with our previous findings demonstrating that FH patients with subclinical lipid-rich atherosclerotic plaques have significantly higher levels blood-derived circulating ℓMVs than those with fibrous plaques (113). Besides, levels of circulating MVs have been found increased in patients with stable CAD, being MVs of endothelial origin (CD144+, CD31+/Annexin V+) and bearing miRNA-199a and miRNA-126 the most associated to major adverse CVEs (17, 146–148).
Acute Coronary Syndromes
Cell-derived cMV levels are profoundly increased in patients with ACS (Table 1). In a study in patients with STEMI, our group has demonstrated increased levels of pan-LMPs (CD45+), including lymphocytes (CD3+) and monocytes (CD14+) within the first hours of the ACS onset, with partial reductions after 72 h, likely because the inflammatory burst occurred at STEMI onset (155). These data are strongly supported by the fact that platelet- and monocyte-derived cMVs also associate with AMI severity (156) and CVD mortality (166), reflecting the sustained underlying endothelial injury and leukocyte and platelet activation in CVD progression after a CVE.
Cerebrovascular Disease
Circulating microvesicles have been associated with ischemic stroke, cerebral vasospasm, lacunar infarcts and multi-infarct dementia, and carotid AT (Table 1). Besides, a recent case-control pilot study suggests that circulating MVs derived from monocytes of M2 phenotype, but not those of M1-phenotype are significantly increased in patients with intracerebral hemorrhage within 12 h of symptom onset (167).
AT-Driven Angiogenesis and Neovascularization: MVs as Therapeutic Vectors
Angiogenesis is an active fine-tuning process of vessel sprouting and growth that depends on a precise interplay between stimulatory and inhibitory signals of ECs, SMCs, and pericytes (168). Notably, recent evidence outlines the importance of EC metabolism for angiogenesis in the context of atherogenesis and AT progression (169). Thus, angiogenic processes have severe consequences on vascular remodeling and plaque stability within vulnerable atherosclerotic plaques (plaque rupture and intra-plaque hemorrhage). The generation of new delicate and frail vessels within the growing atherosclerotic lesion contributes to increase the vulnerability of the plaque to rupture. Intriguingly, it is not fully understood whether an atherosclerotic plaque in the arterial tree will rupture and trigger thrombotic cascade or will stabilize. The highest accumulation of neovessels was found in ACS-related human coronary plaques (170). Paracrine intercellular communication exerted by MVs might play a role in the adaptive response of ischemic tissue to hypoxic stress caused by CVD (171). Interestingly, MVs have been postulated as both pro- and antiangiogenic factors (172–177) (Table 2). Indeed, low levels of eMVs-containing β1-integrin and the enzymatically active MMP-2 and MMP-9 showed to promote angiogenesis whereas high levels abolished the angiogenic effects (76). The effect of MVs on angiogenesis is also highly dependent on the quantity, the parental cell type and cell surface content.
Table 2
| Type of MVs | Source | Function | Mechanism | Reference |
|---|---|---|---|---|
| Platelet-derived MVs | Patients with atherosclerosis | ↑ Neovascularization of CAC | Mediated by RANTES | (178) |
| Healthy donors | ↑ Angiogenesis in vitro and in vivo | Dependent on VEGF | (172) | |
| Healthy donors | ↑ Proliferation, angiogenesis and neurogenesis | Differentiation and proliferation of stem cells mediated by MV growth factors (FGF2, VEGF, and PDGF) | (179) | |
| Healthy rats | Protective effect against cerebral ischemic–reperfusion injury | Mediating remote ischemic preconditioning | (180) | |
| Healthy donors | ↑ Tube formation | Via the pertussis toxin-sensitive G protein and the PI3K pathway | (181) | |
| Healthy donors | ↑ Capillary tube formation and reendothelialization | By sensitization of CXCR4 and growth factors | (182) | |
| Endothelial cell (EC)-derived MVs | Mice ischemic hindlimb muscle | ↑ Postischemic neovascularization | – | (183) |
| Human umbilical vein ECs | ↑ Angiogenesis (with low levels of eMVs) | Through β1-integrin and MMP-2 and -9 | (76) | |
| Human ECs | ↑ Formation of capillary-like structures | By MV-harboring Sonic Hedgehog | (174) | |
| Human coronary artery ECs | ↑ Vascular endothelial repair | Induced by miR-126-containing MVs | (24) | |
| Human microvascular EC | ↑ In vitro tube formation | MV-induced plasmin generation | (184) | |
| Human umbilical vein ECs | ↑ Angiogenesis | By upregulating MMP expression | (185) | |
| Carotid plaque-derived MVs | Endarterectomy specimens | ↑ In vivo the tube formation | In a CD40 ligand-dependent manner | (186) |
| T-lymphocyte-derived MVs | Human lymphoid cells | ↑ Neoangiogenesis | By NO synthesis pathway | (175) |
| Myofibroblasts-derived MVs | Skin wound myofibroblasts | ↑ Capillary formation | – | (187) |
| EPC-derived MVs | EPCs from healthy donors | ↑ Angiogenesis in vitro and in vivo | Through eNOS and PI3K/Akt pathway | (188) |
| MSC-derived MVs | MSC from bone marrow | Promote angiogenesis | – | (189) |
| MSC from bone marrow | ↑ Postischemic angioneurogenesis | – | (190) | |
| MSC from umbilical cord | ↑ Angiogenesis in vitro and in vivo | – | (191) | |
| MSC from umbilical cord | ↑ Angiogenesis in vitro and in vivo | By ↑ VEGF in a HIF-1α independent manner | (192) | |
Proangiogenic potential of distinct cell-derived MVs.
CAC, circulating angiogenic cells; CXCR4, C–X–C chemokine receptor type 4; EPC, endothelial progenitor cell; eNOS, endothelial NO synthase; FGF, fibroblast growth factor; HIF, hypoxia-inducible factor; MSC, mesenchymal stem cell; MMP, matrix metalloproteinase; MV, microvesicle; NO, nitric oxide; PDGF, platelet-derived growth factor; PI3K, phosphatidylinositol-3-kinase; RANTES, regulated on activation, normal T cell expressed and secreted; VEGF, vascular endothelial growth factor; MV, microvesicle; MMP-2, matrix metalloproteinase-2.
Microvesicles from apoptotic ECs (24, 188), endothelial progenitor cells (EPCs) (188), platelets (172, 181, 182, 193, 194), skin wound myofibroblasts (187), and ischemic muscle (183) stimulate endothelial proliferation, survival, migration, repair, and tube formation in vitro by activating pro-angiogenic signaling cascades, such as ERK and PI3K/Akt pathways, or through upregulation of MMP-2 and MMP-9 expression in ECs (185) (Table 2). Leroyer et al. (186) elegantly demonstrated that carotid plaque MVs stimulate both endothelial proliferation and in vivo angiogenesis in a CD40 ligand-dependent manner, which could be modulated by the fibrinolytic activity of eMVs and LMVs (184). Indeed, eMVs play an important role in plasmin formation, which can influence in vitro the tube formation of EPCs in a dose-dependent manner (184).
Other cell-specific MVs have also shown proangiogenic potential (Table 2). pMVs from atherosclerotic patients increased the neovascularization capacity of circulating angiogenic cells through a RANTES-mediated mechanism (178). pMVs not only were shown to stimulate vascular endothelial growth factor (VEGF)-dependent revascularization after chronic cardiac ischemia (172) but also stem cell repair mechanisms after brain ischemia in rats by increasing angiogenesis and neurogenesis at the infarct zone (179). In addition, the remote conditioning protective effect of pMVs was further proved against cerebral ischemic reperfusion injury (180). Increased levels of MVs from ischemic muscle showed to promote postischemic neovascularization in mouse after hindlimb ischemia (HLI) (183). T-lymphocyte-derived ℓMVs enriched with the morphogen sonic hedgehog increased neoangiogenesis and restored endothelial function after injection in mice by stimulating the NO synthesis pathway (175, 195). Endothelial colony-forming cell-derived MVs were demonstrated to be pro-angiogenic both in vitro and in vivo through eNOS and the PI3K/AKT pathway (188). Moreover, MVs from bone marrow-derived mesenchymal stem cells (MSCs) showed proangiogenic activities in a rat MI model contributing to cardiac repair (189) and improved postischemic neuroangiogenesis in a stroke model (190) while MSC–derived MVs from umbilical cord enhanced tube-like structure development and further rescued blood flow in a rat model of HLI (191). Indeed, umbilical cord MSC-derived MVs were shown to enhance angiogenesis in a rat model of kidney ischemia (192), suggesting that MSC-derived MVs might exert cardioprotective effects.
In contrast to the findings reported above, placental MVs have been implicated in antiangiogenic processes contributing to impaired perfusion of placenta in patients with preeclampsia (196). In line with these studies, high levels of eMVs inhibited angiogenesis in the cultured segments of hearts by hampering endothelial nitric oxide synthase (eNOS) regulation (176). Oxidative stress is also involved in the antiangiogenic effect of MVs. Lymphocyte-MVs inhibited angiogenesis regulating negatively VEGF pathway (197) whereas eMVs inhibited in vitro angiogenesis by impairing acetylcholine-induced endothelial vasorelaxation and NO production in rat aortic rings (22, 173). Recently, eMVs were reported to inhibit capillary-like branch structure formation by microvascular ECs (mECs) in vitro and in vivo triggered by ROS via the expression of CD36 on the target EC (198).
Interestingly, the stimulating environment influencing the generation of MVs is able to switch their angiogenic phenotype. Treatment of MSCs with PDGF generated proangiogenic MVs (199), showing that the cargoes of MVs greatly impact on their effects. In agreement, cavin-2 that is released in eMVs and required for eMV biogenesis acts as a regulator of angiogenesis by producing NO and controlling the stability and activity of eNOS (200). Moreover, we found that C-reactive protein (CRP) is pro-angiogenic (201) and interestingly CRP is carried by circulating MVs in ischemic patients (202). eMVs from patients with chronic thromboembolic pulmonary hypertension increased EC endoglin concentration and stimulated endothelial angiogenesis showing a protective mechanism for ED and vascular occlusion (203). Of note, exercise intensity increases the levels of circulating pMVs with proangiogenic potential, which stimulate EC proliferation, migration, and tubule formation (204). Besides, antihypertensive drugs have shown to regulate both eMV generation and angiogenesis (205). Therefore, MVs might be considered as dual-purpose mediators of cell–cell communication in health and disease, greatly depending on the surrounding environment in which they are formed, their content and the pathophysiological context where they exert their functions.
Similarly, MVs from preconditioned adipose-derived stem cells (ASC) showed proangiogenic potential through the release of miR-31 targeting factor-inhibiting HIF-1 and enhancing ASC therapeutic efficacy (206). Indeed, miRNA delivery is a key mechanism involved in the effects of MV-driven angiogenesis such as EPC-MVs promoting neovascularization and impairing muscle damage after HLI (207) or inducing the survival of human islet transplants (208). Thus, eMVs released upon interleukin-3 activation transferred miRNA-126-3p and pSTAT5 into ECs thereby promoting angiogenesis (209). In this regard, MVs containing miRNA-126 stimulate reendothelialization after vascular injury (24) and administration of vesicles containing miR-126 decreased atherosclerotic plaque formation and favored plaque stability in mice (210). Besides, transfer of miRNA-150 to ECs by mMVs also promoted angiogenesis both in vitro and in vivo (117).
Tissue factor, the primary cellular initiator of blood coagulation, is also involved in angiogenic processes (211–213). Proangiogenic signaling through TF-dependent MV-mediated activation of PAR-2 has been reported in hypoxic ECs (214). Besides, TF+-MVs were shown to bind to β1-integrin in the surface of ECs to induce proliferation through ERK1/2 (215). In the same line, we have demonstrated that TF-containing eMVs from microvascular ECs (meMVs) interacted via paracrine signaling with other mECs and triggered angiogenesis ex vivo and postischemic collateral vessel growth in vivo (216). The meMVs proangiogenic potential was shown to be regulated by β1-integrin–EC interactions inducing Rac1–ERK1/2–ETS signaling and CCL2 production (Figure 4). Taken together, MVs can overwhelm the effects of arterial occlusion and tissue ischemia by stimulating postischemic neovascularization together with tissue reperfusion. Beyond being a promising therapeutic strategy for treating ischemic diseases (217), angiogenesis has also a role in the context of tumor progression and cancer, in which distinct types of MVs by means of cell-cell communication have also a regulatory function (14, 218–228). It is important to join efforts toward the ultimate goal of reaching therapeutical applications of MVs into the clinical arena.
Figure 4
Pharmacological and Non-Pharmacological Intervention
A deep understanding of the role of MVs in AT might be fundamental for both CVD risk factor control and therapeutic treatment (130). Non-pharmacological interventions lie in overcoming CVRF by lifestyle modifications, such as exercise and diet. In primary prevention, a recent clinical trial showed the benefit of the adherence to the Mediterranean diet in patients at high cardiovascular risk in relation to the incidence of severe CVEs (229). Within the same population, our group has recently demonstrated that decreased levels of cMVs derived from ECs, leukocytes and activated platelets could signal for a reduced rate of major CVEs in high-risk patients under state-of-the-art treatment and receiving a controlled MedDiet supplemented with nuts (230). Dietary modulation of MV release is a relatively new field of study based mainly on short-term studies; further large-scale studies will help to better understand the complex relationship between diet and CVD.
Several drugs have shown to influence cMVs levels (231, 232), their cargoes (233) and even their function (Table 3). For instance, berberine improved endothelial function by reducing CD31+/CD42− eMVs and thereby levels of oxidative stress in humans (234, 235) and the adhesion of monocytes to ECs was partially prevented by eMVs after lipid-lowering and antihypertensive treatments (236). Since MV biogenesis and release is not fully understood, distinct therapeutic options are under investigation. Reduced levels of pMVs are associated with the use of distinct anti-platelet drugs such as GPIIb/IIIa inhibitors (237, 238), clopidogrel (239, 240), ticlopidine (121, 122), and acetylsalicylic acid (ASA) (241). In patients under antithrombotic therapy, P-Sel and TF-containing pMVs remain high 6 months after treatment initiation (242), likely due to the fact that low doses of ASA might not be potent enough to prevent the release of pMVs into the microcirculation (243). Our group has reported that ASA intake in patients with diabetes in primary prevention has no effect on pMVs (244). Similarly, antihypertensive drugs like angiotensin II receptor antagonists (245) and calcium channel blockers (246), antioxidants (247), peroxisome proliferator-activator receptor activators (248, 249), hydroxyurea in sickle cell disease (250), and eculizumab in paroxysmal nocturnal hemoglobinuria (251) have also shown influence on MV shedding. Up to now the effect of statins, the cornerstone drugs for lipid-lowering treatment (LLT) in CVD prevention, has been highly debated. While some authors demonstrated that statins may enhance the shedding of MVs (252, 253) many studies have found that statin treatment promote MV inhibition (88, 135, 254–256). Thus, pravastatin and simvastatin decreased pMVs in hypertensive (257) and type-2 diabetic (88, 120) patients. Similarly, atorvastatin diminished the formation of thrombin and the expression of P-Sel, TF, and GPIIIa on pMVs in patients with peripheral artery disease (233) and with dyslipidemia and type-1 diabetes (258). Indeed, in a study focused on the effects of LLT on levels of cMV in atherosclerotic patients in primary prevention, we have reported that the plasma of LLT-treated patients presented lower quantity of MVs and lower content of cell surface activation markers than the plasma from untreated patients with the same blood cholesterol levels (255), indicating a direct benefit of LLT with statins in reducing cell membrane shedding, which may have effects in the beneficial protection against AT characteristic of statins by inhibiting MV generation and the triggering of MV-dependent mechanisms. These data are in agreement to results pointing out the broader use of statins decreasing inflammation and suppressing MV release, an effect that is not shown neither with ezetimibe alone (259) nor with ezetimibe combined with statins (260). Furthermore, several inhibitors of MV shedding such as ROCK inhibitors or calpain, among others, are currently under study. Nevertheless, whether the clinical benefit of these pharmacological strategies is directly related to MV decrease deserves further research.
Table 3
| Type of drug | Therapy dose | Subjects (N) | MV change | Reference | ||
|---|---|---|---|---|---|---|
| Anti-platelet | ||||||
| GPIIb/IIIa inhibitors | Abciximab: 250 μg/kg bolus + 12 h 0.125 μg/kg/min Eptifibatide: 180 μg/kg bolus + 18 h 2 μg/kg/min | 50 ST-segment elevation patients undergoing percutaneous coronary intervention | ↓ GPIV+-pMVs ↓ CD11a+-LMVs | (238) | ||
| Clopidogrel | 4 weeks, 75 mg/day | 26 patients with stable coronary artery disease (CAD) | = CD51+-eMVs ↓ CD42+/CD31+-pMV | (240) | ||
| Probucol and ticlopidine | 6 months Probucol: 500 mg/day Ticlopidine: 200 mg/day | 23 normolipidemic controls and 53 hyperlipidemic patients | ↓ CD62P+-pMVs ↓ CD63+-pMVs ↓ Annexin V+-MVs ↓ CD14+-mMVs | (121) | ||
| Ticlopidine | 1 month, 200 mg/day | 21 type-2 diabetic patients | ↓ CD62P+-pMVs ↓ CD14+-mMVs | (122) | ||
| Acetylsalicylic acid | 8 weeks, 100 mg/day | 15 patients with CAD | ↓ eMVs ↓ pMVs | (241) | ||
| 6 months, bolus of 500 mg and 75 mg/day | 51 patients with acute coronary syndromes | ↑ CD62P+-pMVs ↑ CD142+-pMVs | (242) | |||
| 10 days, 100 mg/day | 43 patients with diabetes | = pMVs | (244) | |||
| Cilostazol | 1 month, 150 mg/day | 30 controls and 43 non-insulin dependent diabetes mellitus | ↓ CD62P+-pMVs ↓ CD63+-pMVs ↓ Annexin V+-MVs | (231) | ||
| Antihypertensive | ||||||
| Angiotensin II receptor antagonists | Eprosartan: 2 months, 600 mg/day | 31 hypertensive and 31 normotensive patients | ↓ CD42b+-pMVs | (245) | ||
| Losartan and simvastatin | 24 weeks Losartan: 50 mg/day Simvastatin: 10 mg/day | 41 hypertensive patients with hyperlipidemia and/or type-2 diabetes | ↓ KMP9+-pMVs ↓ CD51+-eMVs | (135) | ||
| Anti-diabetic | ||||||
| Miglitol | 1 month, 150 mg/day | 72 non-diabetic patients (37 with hypertension, 35 with hyperlipidemia) and 38 diabetic patients | ↓ CD42a/b+-pMVs | (232) | ||
| Berberine | 1 month, 1.2 g/day | 14 vs. 11 healthy subjects | ↓ CD31+/CD42− eMVs | (234) | ||
| 1 month, 1.2 g/day | 12 vs. 11 healthy subjects | ↓ CD31+/CD42− eMVs | (235) | |||
| Lipid lowering | ||||||
| Statins | Pravastatin: 8 weeks, 40 mg/day | 50 patients with type-2 diabetes | ↓ CD61+-pMVs | (88) | ||
| Atorvastatin: 8 weeks, 80 mg/day | 19 patients with peripheral arterial occlusive disease and hypercholesterolemia | ↓ CD62P+-pMVs ↓ CD142+-pMVs ↓ CD41+-pMVs | (233) | |||
| Atorvastatin: 80 mg/day | 19 patients with peripheral arterial occlusive disease | ↓ CD62P+-pMVs ↓ CD142+-pMVs ↑ CD144+-eMVs | (253) | |||
| Simvastatin: 80 mg/day; pravastatin: 40 mg/day; lovastatin: 80 mg/day; fluvastatin: 80 mg/day; atorvastatin: 80 mg/day; rosuvastatin: 20–40 mg/day | 37 hypercholesterolaemic patients and 37 normocholesterolaemic controls | ↓ CD41+/61+-pMVs ↓ CD146+/31+-eMVs ↓ CD45+-LMVs ↓ CD14+-mMVs ↓ CD142+-MVs | (255) | |||
| Simvastatin: 6 months, 20 mg/day | 21 hyperlipidemic patients | ↓ CD61+-pMVs | (256) | |||
| Simvastatin: 24 weeks, 10 mg/day | 41 hypertensive patients | ↓ KMP9+-pMVs | (257) | |||
| Atorvastatin: 2 months, 20 mg/day | 20 patients with type 1 diabetes and dyslipidemia | ↓ pMVs | (258) | |||
| Ezetimibe | 10 mg/day | 63 patients with coronary heart disease | = MVs | (259) | ||
| Ezetimibe with statins | Atorvastatin 80 mg/day vs. atorvastatin 20 mg/day plus ezetimibe 10 mg/day | 75 high-risk subjects | ↓ pMV with high-dose statin monotherapy | (260) | ||
Main studies evaluating the effects of pharmacological therapies on circulating microvesicles.
MV, microvesicle; eMVs, endothelial-derived microvesicles; LMVs, leukocyte-derived microvesicles; mMVs, monocyte-derived microvesicles; MVs, microvesicles; pMVs, platelet-derived microvesicles.
Therapeutic Potential
In addition to pharmacological modulation, the advantageous characteristics of cell-derived MVs, which are a naturally produced therapeutic agents with potential to be used as delivery drugs to specific cell types (261), open up their potential therapeutic application, especially in cardiac cell therapy. Preclinical studies demonstrated that treatment with the vesicular fraction of the conditioned media of hypoxic MSCs decreased infarct size and improved cardiac function by decreasing oxidative stress, enhancing myocardial viability, and preventing damage to the heart after MI in mouse and pig models (262–264). The mechanism of action might involve the transfer of specific RNAs through embryonic stem cell MVs (265). MSC-derived MVs were able to face the detrimental effects of ischemia and reperfusion (I/R) injury in the kidney (266). Similarly, MVs derived from myocardial ischemia could protect hearts from I/R injury in rats through calcium regulatory proteins to alleviate intrinsic myocardial mitochondrial and endoplasmic reticulum apoptotic pathways (267). Interestingly, the effect of cardiosphere-derived cells (CDC) on the therapeutic regeneration of the infarcted myocardium shown in a clinical trial (268) seems to be mediated by CDC-derived extracellular vesicles (269). ECs have also been shown to be atheroprotective by transferring miRNAs via MVs to SMCs (81). Specifically, MVs transported functional miR-143/145 into SMCs after activation by shear stress and they reduced atherosclerotic lesion formation in the aorta. Furthermore, a promising therapeutic application of MVs is the use of synthetic MVs mimicking the natural ones. MV delivery could be clinically useful in several conditions such as MI and inflammatory pathologies. Indeed, a recent work reported that infusion of artificially produced MVs can improve inflammation and ameliorate symptoms in different mouse models of MI, multiple sclerosis, and kidney injury (270). Therapeutic innovation of MVs is still in its infancy, and its applicability is hampered by many shortcomings, such as the in vivo biodistribution of MVs that depends on their cellular origin, their half-life and the route of administration (271). Further understanding of the biological mechanisms, efficiency and feasibility of these MV-based therapies is warranted.
Conclusion and Future Perspectives
Microvesicles actively contribute to AT progression and complication due to their implicit role in cell-to-cell communication. cMVs not only play a direct biological role in AT and neoangiogenensis but also might be susceptible targets for pharmacological modulation and emerge as potential prognostic and diagnostic biomarkers of atherothrombotic CVD. However, limitations and technological constraints have precluded the complete understanding of mechanisms of MV formation and pathophysiological relevance. Most functional effects of MVs have been evidenced in in vitro studies with a predetermined MV concentration that is not always comparable to the pathophysiological situation while their exact role in the clinical setting is dismissed. Despite cMVs emerge as promising biomarker candidates, clinical studies in larger cohorts are required to clearly delineate their role as diagnostic and prognostic markers of disease. Until now, the lack of standardization in preanalytical phase guidelines, the difficult implementation as routine in the clinical laboratory as well as the high cost of cMV measurements have curbed their full clinical characterization. However, recent and advanced sensitive technologies together with consensus within the scientific community will undoubtedly shed light on the cMV potential as biomarkers. Besides, exploring the cMV specific targeting to a selective tissue, how they are produced in vivo and their specific genomic, transcriptomic, metabolomic and proteomic content is essential to design efficient therapeutically strategies involving MVs. In the next coming years, we will witness advances and breakthroughs in the area of MVs that will translate into their use in diagnostic and therapeutic innovation.
Statements
Author contributions
LB, RS, and TP conceived and coordinated the design of the review and wrote the paper. RS made figures. LB and RS edited the paper. All the authors wrote part of the manuscript, provided critical comments, revised the manuscript, and approved the final version of the manuscript.
Funding
This work was supported by the Spanish Ministry of Economy and Competitiveness Plan Estatal I+D+I [SAF2016-76819-R], the Institute of Health Carlos III-ISCIII [CIBERCV CN16/11/00411 and TERCEL RD16/0011/018 to LB, FIS PI16/01915 to TP], and by the Fondo Europeo de Desarrollo Regional (FEDER—“Una manera de hacer Europa”). The authors thank the continuous support of the Generalitat of Catalunya (Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat; 2014SGR1303). RS is a postdoctoral fellow funded by Daniel Bravo Andreu Foundation.
Acknowledgments
The continuous support of Fundación Investigación Cardiovascular—F. Jesus Serra (Spain) to the Cardiovascular Research Chair-UAB (LB) is gratefully acknowledged.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Abbreviations
AT, atherosclerosis; CAD, coronary artery disease; cMV, circulating microvesicle; CVD, cardiovascular disease; CVE, cardiovascular event; EC, endothelial cell; eMV, endothelial-derived microvesicle; EPC, endothelial progenitor cell; ErMV, erythrocyte-derived microvesicle; ICAM, intercellular cell adhesion molecule; I/R, ischemia and reperfusion; LDL, low-density lipoprotein; ℓMV, lymphocyte-derived microvesicle; LMV, leukocyte-derived microvesicle; LLT, lipid-lowering treatment; mEC, microvascular endothelial cell; meMV, microvascular endothelial-derived microvesicle; MetDiet, Mediterranean diet; miRNA, microRNA; MMP, matrix metalloproteinase; mMV, monocyte-derived microvesicle; MP, microparticle; MSC, mesenchymal stem cell; MV, microvesicle; NO, nitric oxide; pMV, platelet-derived microvesicle; PS, phosphatidylserine; RNA, ribonucleic acid; ROS, reactive oxygen species; SMC, smooth muscle cell; TF, tissue factor; T2D, type 2 diabetes; VCAM, vascular cell adhesion molecule.
References
1
Santos-GallegoCGPicatosteBBadimonJJ. Pathophysiology of acute coronary syndrome. Curr Atheroscler Rep (2014) 16:401.10.1007/s11883-014-0401-9
2
SuadesRPadroTBadimonL. The role of blood-borne microparticles in inflammation and hemostasis. Semin Thromb Hemost (2015) 41:590–606.10.1055/s-0035-1556591
3
BadimonLSuadesRFuentesEPalomoIPadroT. Role of platelet-derived microvesicles as crosstalk mediators in atherothrombosis and future pharmacology targets: a link between inflammation, atherosclerosis, and thrombosis. Front Pharmacol (2016) 7:293.10.3389/fphar.2016.00293
4
van der polEBoingANGoolELNieuwlandR. Recent developments in the nomenclature, presence, isolation, detection and clinical impact of extracellular vesicles. J Thromb Haemost (2016) 14:48–56.10.1111/jth.13190
5
ZhangYLiuDChenXLiJLiLBianZet alSecreted monocytic miR-150 enhances targeted endothelial cell migration. Mol Cell (2010) 39:133–44.10.1016/j.molcel.2010.06.010
6
ConnorDEExnerTMaDDJosephJE. The majority of circulating platelet-derived microparticles fail to bind annexin V, lack phospholipid-dependent procoagulant activity and demonstrate greater expression of glycoprotein Ib. Thromb Haemost (2010) 103:1044–52.10.1160/TH09-09-0644
7
ArraudNLinaresRTanSGounouCPasquetJMMornetSet alExtracellular vesicles from blood plasma: determination of their morphology, size, phenotype and concentration. J Thromb Haemost (2014) 12:614–27.10.1111/jth.12554
8
GacebAMartinezMCAndriantsitohainaR. Extracellular vesicles: new players in cardiovascular diseases. Int J Biochem Cell Biol (2014) 50:24–8.10.1016/j.biocel.2014.01.018
9
CoumansFAWGoolELNieuwlandR. Bulk immunoassays for analysis of extracellular vesicles. Platelets (2017) 28:242–8.10.1080/09537104.2016.1265926
10
CoumansFAWBrissonARBuzasEIDignat-GeorgeFDreesEEEEl-AndaloussiSet alMethodological guidelines to study extracellular vesicles. Circ Res (2017) 120:1632–48.10.1161/CIRCRESAHA.117.309417
11
RidgerVCBoulangerCMAngelillo-ScherrerABadimonLBlanc-BrudeOBochaton-PiallatMLet alMicrovesicles in vascular homeostasis and diseases. Position Paper of the European Society of Cardiology (ESC) working group on atherosclerosis and vascular biology. Thromb Haemost (2017) 117:1296–316.10.1160/TH16-12-0943
12
SzatanekRBaj-KrzyworzekaMZimochJLekkaMSiedlarMBaranJ. The methods of choice for extracellular vesicles (EVs) characterization. Int J Mol Sci (2017) 18(6):ii:E1153.10.3390/ijms18061153
13
ValkonenSVan Der PolEBoingAYuanaYYliperttulaMNieuwlandRet alBiological reference materials for extracellular vesicle studies. Eur J Pharm Sci (2017) 98:4–16.10.1016/j.ejps.2016.09.008
14
SkogJWurdingerTVan RijnSMeijerDHGaincheLSena-EstevesMet alGlioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol (2008) 10:1470–6.10.1038/ncb1800
15
AmabileNGuerinAPLeroyerAMallatZNguyenCBoddaertJet alCirculating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. J Am Soc Nephrol (2005) 16:3381–8.10.1681/ASN.2005050535
16
LinZBCiHBLiYChengTPLiuDHWangYSet alEndothelial microparticles are increased in congenital heart diseases and contribute to endothelial dysfunction. J Transl Med (2017) 15:4.10.1186/s12967-016-1087-2
17
WernerNWassmannSAhlersPKosiolSNickenigG. Circulating CD31+/annexin V+ apoptotic microparticles correlate with coronary endothelial function in patients with coronary artery disease. Arterioscler Thromb Vasc Biol (2006) 26:112–6.10.1161/01.ATV.0000191634.13057.15
18
ChenYFengBLiXNiYLuoY. Plasma endothelial microparticles and their correlation with the presence of hypertension and arterial stiffness in patients with type 2 diabetes. J Clin Hypertens (Greenwich) (2012) 14:455–60.10.1111/j.1751-7176.2012.00631.x
19
FengBChenYLuoYChenMLiXNiY. Circulating level of microparticles and their correlation with arterial elasticity and endothelium-dependent dilation in patients with type 2 diabetes mellitus. Atherosclerosis (2010) 208:264–9.10.1016/j.atherosclerosis.2009.06.037
20
HuSSZhangHGZhangQJXiuRJ. CD51+ endothelial microparticles as a biomarker of endothelial dysfunction in obese patients with hypertension. Endocrine (2015) 49:283–5.10.1007/s12020-014-0423-7
21
MartinSTesseAHugelBMartinezMCMorelOFreyssinetJMet alShed membrane particles from T lymphocytes impair endothelial function and regulate endothelial protein expression. Circulation (2004) 109:1653–9.10.1161/01.CIR.0000124065.31211.6E
22
BrodskySVZhangFNasjlettiAGoligorskyMS. Endothelium-derived microparticles impair endothelial function in vitro. Am J Physiol Heart Circ Physiol (2004) 286:H1910–5.10.1152/ajpheart.01172.2003
23
DensmoreJCSignorinoPROuJHatoumOARoweJJShiYet alEndothelium-derived microparticles induce endothelial dysfunction and acute lung injury. Shock (2006) 26:464–71.10.1097/01.shk.0000228791.10550.36
24
JansenFYangXHoelscherMCattelanASchmitzTProebstingSet alEndothelial microparticle-mediated transfer of microRNA-126 promotes vascular endothelial cell repair via SPRED1 and is abrogated in glucose-damaged endothelial microparticles. Circulation (2013) 128:2026–38.10.1161/CIRCULATIONAHA.113.001720
25
SafiedeenZRodriguez-GomezIVergoriLSoletiRVaithilingamDDoumaIet alTemporal cross talk between endoplasmic reticulum and mitochondria regulates oxidative stress and mediates microparticle-induced endothelial dysfunction. Antioxid Redox Signal (2017) 26:15–27.10.1089/ars.2016.6771
26
IshidaKTaguchiKHidaMWatanabeSKawanoKMatsumotoTet alCirculating microparticles from diabetic rats impair endothelial function and regulate endothelial protein expression. Acta Physiol (Oxf) (2016) 216:211–20.10.1111/apha.12561
27
BoulangerCMScoazecAEbrahimianTHenryPMathieuETedguiAet alCirculating microparticles from patients with myocardial infarction cause endothelial dysfunction. Circulation (2001) 104:2649–52.10.1161/hc4701.100516
28
AgouniALagrue-Lak-HalAHDucluzeauPHMostefaiHADraunet-BussonCLeftheriotisGet alEndothelial dysfunction caused by circulating microparticles from patients with metabolic syndrome. Am J Pathol (2008) 173:1210–9.10.2353/ajpath.2008.080228
29
FuLHuXXLinZBChangFJOuZJWangZPet alCirculating microparticles from patients with valvular heart disease and cardiac surgery inhibit endothelium-dependent vasodilation. J Thorac Cardiovasc Surg (2015) 150:666–72.10.1016/j.jtcvs.2015.05.069
30
YeSShanXFHanWQZhangQRGaoJJinAPet alMicroparticles from patients undergoing percutaneous coronary intervention impair vasodilatation by uncoupling endothelial nitric oxide synthase. Shock (2017) 48:201–8.10.1097/SHK.0000000000000823
31
AbbasMJeselLAugerCAmouraLMessasNManinGet alEndothelial microparticles from acute coronary syndrome patients induce premature coronary artery endothelial cell aging and thrombogenicity: role of the Ang II/AT1 receptor/NADPH oxidase-mediated activation of MAPKs and PI3-kinase pathways. Circulation (2017) 135:280–96.10.1161/CIRCULATIONAHA.116.017513
32
HornPCortese-KrottMMAmabileNHundsdorferCKronckeKDKelmMet alCirculating microparticles carry a functional endothelial nitric oxide synthase that is decreased in patients with endothelial dysfunction. J Am Heart Assoc (2012) 2:e003764.10.1161/JAHA.112.003764
33
MahmoudAMWilkinsonFLMccarthyEMMoreno-MartinezDLangford-SmithARomeroMet alEndothelial microparticles prevent lipid-induced endothelial damage via Akt/eNOS signaling and reduced oxidative stress. FASEB J (2017) 31:4636–48.10.1096/fj.201601244RR
34
EdrissiHSchockSCHakimAMThompsonCS. Microparticles generated during chronic cerebral ischemia increase the permeability of microvascular endothelial barriers in vitro. Brain Res (2016) 1634:83–93.10.1016/j.brainres.2015.12.032
35
MesriMAltieriDC. Leukocyte microparticles stimulate endothelial cell cytokine release and tissue factor induction in a JNK1 signaling pathway. J Biol Chem (1999) 274:23111–8.10.1074/jbc.274.33.23111
36
NomuraSTandonNNNakamuraTConeJFukuharaSKambayashiJ. High-shear-stress-induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells. Atherosclerosis (2001) 158:277–87.10.1016/S0021-9150(01)00433-6
37
BarryOPPraticoDSavaniRCFitzgeraldGA. Modulation of monocyte-endothelial cell interactions by platelet microparticles. J Clin Invest (1998) 102:136–44.10.1172/JCI2592
38
MesriMAltieriDC. Endothelial cell activation by leukocyte microparticles. J Immunol (1998) 161:4382–7.
39
MezianiFDelabrancheXAsfarPTotiF. Bench-to-bedside review: circulating microparticles – a new player in sepsis?Crit Care (2010) 14:236.10.1186/cc9231
40
WangJGWilliamsJCDavisBKJacobsonKDoerschukCMTingJPet alMonocytic microparticles activate endothelial cells in an IL-1beta-dependent manner. Blood (2011) 118:2366–74.10.1182/blood-2011-01-330878
41
HeinrichLFAndersenDKCleasbyMELawsonC. Long-term high fat feeding of rats results in increased numbers of circulating microvesicles with pro-inflammatory effects on endothelial cells. Br J Nutr (2015) 113:1704–11.10.1017/S0007114515001117
42
CurtisAMWilkinsonPFGuiMGalesTLHuEEdelbergJM. p38 mitogen-activated protein kinase targets the production of proinflammatory endothelial microparticles. J Thromb Haemost (2009) 7:701–9.10.1111/j.1538-7836.2009.03304.x
43
FinkKMoebesMVetterCBourgeoisNSchmidBBodeCet alSelenium prevents microparticle-induced endothelial inflammation in patients after cardiopulmonary resuscitation. Crit Care (2015) 19:58.10.1186/s13054-015-0774-3
44
JansenFYangXBaumannKPrzybillaDSchmitzTFlenderAet alEndothelial microparticles reduce ICAM-1 expression in a microRNA-222-dependent mechanism. J Cell Mol Med (2015) 19:2202–14.10.1111/jcmm.12607
45
HuberJValesAMitulovicGBlumerMSchmidRWitztumJLet alOxidized membrane vesicles and blebs from apoptotic cells contain biologically active oxidized phospholipids that induce monocyte-endothelial interactions. Arterioscler Thromb Vasc Biol (2002) 22:101–7.10.1161/hq0102.101525
46
MauseSFVon HundelshausenPZerneckeAKoenenRRWeberC. Platelet microparticles: a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium. Arterioscler Thromb Vasc Biol (2005) 25:1512–8.10.1161/01.ATV.0000170133.43608.37
47
RautouPELeroyerASRamkhelawonBDevueCDuflautDVionACet alMicroparticles from human atherosclerotic plaques promote endothelial ICAM-1-dependent monocyte adhesion and transendothelial migration. Circ Res (2011) 108:335–43.10.1161/CIRCRESAHA.110.237420
48
NjockMSChengHSDangLTNazari-JahantighMLauACBoudreauEet alEndothelial cells suppress monocyte activation through secretion of extracellular vesicles containing antiinflammatory microRNAs. Blood (2015) 125:3202–12.10.1182/blood-2014-11-611046
49
ForlowSBMceverRPNollertMU. Leukocyte-leukocyte interactions mediated by platelet microparticles under flow. Blood (2000) 95(4):1317–23.
50
KeyelPATkachevaOALarreginaATSalterRD. Coordinate stimulation of macrophages by microparticles and TLR ligands induces foam cell formation. J Immunol (2012) 189:4621–9.10.4049/jimmunol.1200828
51
LeeSKYangSHKwonILeeOHHeoJH. Role of tumour necrosis factor receptor-1 and nuclear factor-kappaB in production of TNF-alpha-induced pro-inflammatory microparticles in endothelial cells. Thromb Haemost (2014) 112:580–8.10.1160/TH13-11-0975
52
Abid HusseinMNNieuwlandRHauCMEversLMMeestersEWSturkA. Cell-derived microparticles contain caspase 3 in vitro and in vivo. J Thromb Haemost (2005) 3:888–96.10.1111/j.1538-7836.2005.01240.x
53
DistlerJHHuberLCHueberAJReichCFIIIGaySDistlerOet alThe release of microparticles by apoptotic cells and their effects on macrophages. Apoptosis (2005) 10:731–41.10.1007/s10495-005-2941-5
54
HuberLCJungelADistlerJHMoritzFGayREMichelBAet alThe role of membrane lipids in the induction of macrophage apoptosis by microparticles. Apoptosis (2007) 12:363–74.10.1007/s10495-006-0622-7
55
BoingANHauCMSturkANieuwlandR. Platelet microparticles contain active caspase 3. Platelets (2008) 19:96–103.10.1080/09537100701777295
56
SarkarAMitraSMehtaSRaicesRWewersMD. Monocyte derived microvesicles deliver a cell death message via encapsulated caspase-1. PLoS One (2009) 4:e7140.10.1371/journal.pone.0007140
57
LeroyerASIsobeHLesecheGCastierYWassefMMallatZet alCellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic plaques. J Am Coll Cardiol (2007) 49:772–7.10.1016/j.jacc.2006.10.053
58
MayrMGraingerDMayrULeroyerASLesecheGSidibeAet alProteomics, metabolomics, and immunomics on microparticles derived from human atherosclerotic plaques. Circ Cardiovasc Genet (2009) 2:379–88.10.1161/CIRCGENETICS.108.842849
59
NiessenAHeyderPKrienkeSBlankNTykocinskiLOLorenzHMet alApoptotic-cell-derived membrane microparticles and IFN-alpha induce an inflammatory immune response. J Cell Sci (2015) 128:2443–53.10.1242/jcs.162735
60
ClassenLTykocinskiLOWiedmannFBirrCSchillerPTucherCet alExtracellular vesicles mediate intercellular communication: transfer of functionally active microRNAs by microvesicles into phagocytes. Eur J Immunol (2017) 47(9):1535–49.10.1002/eji.201646595
61
Llorente-CortesVOtero-VinasMCamino-LopezSLlampayasOBadimonL. Aggregated low-density lipoprotein uptake induces membrane tissue factor procoagulant activity and microparticle release in human vascular smooth muscle cells. Circulation (2004) 110:452–9.10.1161/01.CIR.0000136032.40666.3D
62
PakalaR. Serotonin and thromboxane A2 stimulate platelet-derived microparticle-induced smooth muscle cell proliferation. Cardiovasc Radiat Med (2004) 5:20–6.10.1016/j.carrad.2003.12.002
63
WeberAKoppenHOSchrorK. Platelet-derived microparticles stimulate coronary artery smooth muscle cell mitogenesis by a PDGF-independent mechanism. Thromb Res (2000) 98:461–6.10.1016/S0049-3848(00)00192-4
64
Kelly-ArnoldAMaldonadoNLaudierDAikawaECardosoLWeinbaumS. Revised microcalcification hypothesis for fibrous cap rupture in human coronary arteries. Proc Natl Acad Sci U S A (2013) 110:10741–6.10.1073/pnas.1308814110
65
BadimonLVilahurG. Thrombosis formation on atherosclerotic lesions and plaque rupture. J Intern Med (2014) 276:618–32.10.1111/joim.12296
66
SangiorgiGRumbergerJASeversonAEdwardsWDGregoireJFitzpatrickLAet alArterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: a histologic study of 723 coronary artery segments using nondecalcifying methodology. J Am Coll Cardiol (1998) 31:126–33.10.1016/S0735-1097(97)00443-9
67
OtsukaFSakakuraKYahagiKJonerMVirmaniR. Has our understanding of calcification in human coronary atherosclerosis progressed?Arterioscler Thromb Vasc Biol (2014) 34:724–36.10.1161/ATVBAHA.113.302642
68
HuangHVirmaniRYounisHBurkeAPKammRDLeeRT. The impact of calcification on the biomechanical stability of atherosclerotic plaques. Circulation (2001) 103:1051–6.10.1161/01.CIR.103.8.1051
69
HsuJJLimJTintutYDemerLL. Cell-matrix mechanics and pattern formation in inflammatory cardiovascular calcification. Heart (2016) 102:1710–5.10.1136/heartjnl-2016-309667
70
ReynoldsJLJoannidesAJSkepperJNMcnairRSchurgersLJProudfootDet alHuman vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol (2004) 15:2857–67.10.1097/01.ASN.0000141960.01035.28
71
NewSEGoettschCAikawaMMarchiniJFShibasakiMYabusakiKet alMacrophage-derived matrix vesicles: an alternative novel mechanism for microcalcification in atherosclerotic plaques. Circ Res (2013) 113:72–7.10.1161/CIRCRESAHA.113.301036
72
BuendiaPMontes De OcaAMaduenoJAMerinoAMartin-MaloAAljamaPet alEndothelial microparticles mediate inflammation-induced vascular calcification. FASEB J (2015) 29:173–81.10.1096/fj.14-249706
73
GoettschCHutchesonJDAikawaMIwataHPhamTNykjaerAet alSortilin mediates vascular calcification via its recruitment into extracellular vesicles. J Clin Invest (2016) 126:1323–36.10.1172/JCI80851
74
GasserOHessCMiotSDeonCSanchezJCSchifferliJA. Characterisation and properties of ectosomes released by human polymorphonuclear neutrophils. Exp Cell Res (2003) 285:243–57.10.1016/S0014-4827(03)00055-7
75
FolkessonMLiCFrebeliusSSwedenborgJWagsaterDWilliamsKJet alProteolytically active ADAM10 and ADAM17 carried on membrane microvesicles in human abdominal aortic aneurysms. Thromb Haemost (2015) 114:1165–74.10.1160/TH14-10-0899
76
TarabolettiGD’AscenzoSBorsottiPGiavazziRPavanADoloV. Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells. Am J Pathol (2002) 160:673–80.10.1016/S0002-9440(10)64887-0
77
LozitoTPTuanRS. Endothelial cell microparticles act as centers of matrix metalloproteinsase-2 (MMP-2) activation and vascular matrix remodeling. J Cell Physiol (2012) 227:534–49.10.1002/jcp.22744
78
Martinez de LizarrondoSRoncalCCalvayracORodriguezCVaroNPurroyAet alSynergistic effect of thrombin and CD40 ligand on endothelial matrix metalloproteinase-10 expression and microparticle generation in vitro and in vivo. Arterioscler Thromb Vasc Biol (2012) 32:1477–87.10.1161/ATVBAHA.112.248773
79
CanaultMLeroyerASPeirettiFLesecheGTedguiABonardoBet alMicroparticles of human atherosclerotic plaques enhance the shedding of the tumor necrosis factor-alpha converting enzyme/ADAM17 substrates, tumor necrosis factor and tumor necrosis factor receptor-1. Am J Pathol (2007) 171:1713–23.10.2353/ajpath.2007.070021
80
BobryshevYVKillingsworthMCOrekhovAN. Increased shedding of microvesicles from intimal smooth muscle cells in athero-prone areas of the human aorta: implications for understanding of the predisease stage. Pathobiology (2013) 80:24–31.10.1159/000339430
81
HergenreiderEHeydtSTreguerKBoettgerTHorrevoetsAJZeiherAMet alAtheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nat Cell Biol (2012) 14:249–56.10.1038/ncb2441
82
ShanZQinSLiWWuWYangJChuMet alAn endocrine genetic signal between blood cells and vascular smooth muscle cells: role of microRNA-223 in smooth muscle function and atherogenesis. J Am Coll Cardiol (2015) 65:2526–37.10.1016/j.jacc.2015.03.570
83
MallatZHugelBOhanJLesecheGFreyssinetJMTedguiA. Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation (1999) 99:348–53.10.1161/01.CIR.99.3.348
84
WolfP. The nature and significance of platelet products in human plasma. Br J Haematol (1967) 13:269–88.10.1111/j.1365-2141.1967.tb08741.x
85
SinauridzeEIKireevDAPopenkoNYPichuginAVPanteleevMAKrymskayaOVet alPlatelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost (2007) 97(3):425–34.10.1160/TH06-06-0313
86
NomuraSKomiyamaYMurakamiTFunatsuAKokawaTSugoTet alFlow cytometric analysis of surface membrane proteins on activated platelets and platelet-derived microparticles from healthy and thrombasthenic individuals. Int J Hematol (1993) 58:203–12.
87
FalatiSLiuQGrossPMerrill-SkoloffGChouJVandendriesEet alAccumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med (2003) 197:1585–98.10.1084/jem.20021868
88
SommeijerDWJoopKLeyteAReitsmaPHTen CateH. Pravastatin reduces fibrinogen receptor gpIIIa on platelet-derived microparticles in patients with type 2 diabetes. J Thromb Haemost (2005) 3:1168–71.10.1111/j.1538-7836.2005.01403.x
89
RaturiAMierschSHudsonJWMutusB. Platelet microparticle-associated protein disulfide isomerase promotes platelet aggregation and inactivates insulin. Biochim Biophys Acta (2008) 1778:2790–6.10.1016/j.bbamem.2008.07.003
90
ScholzTTemmlerUKrauseSHeptinstallSLoscheW. Transfer of tissue factor from platelets to monocytes: role of platelet-derived microvesicles and CD62P. Thromb Haemost (2002) 88(6):1033–8.
91
Del CondeIShrimptonCNThiagarajanPLopezJA. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood (2005) 106:1604–11.10.1182/blood-2004-03-1095
92
CollierMCollierMEWEttelaieCGoultBTMaraveyasAGoodallAH. Investigation of the filamin A-dependent mechanisms of tissue factor incorporation into microvesicles. Thromb Haemost (2017) 117(11):2034–44.10.1160/TH17-01-0009
93
BodenGRaoAK. Effects of hyperglycemia and hyperinsulinemia on the tissue factor pathway of blood coagulation. Curr Diab Rep (2007) 7:223–7.10.1007/s11892-007-0035-1
94
TsimermanGRoguinABacharAMelamedEBrennerBAharonA. Involvement of microparticles in diabetic vascular complications. Thromb Haemost (2011) 106:310–21.10.1160/TH10-11-0712
95
StojkovicSThulinAHellLThalerBRauscherSBaumgartnerJet alIL-33 stimulates the release of procoagulant microvesicles from human monocytes and differentially increases tissue factor in human monocyte subsets. Thromb Haemost (2017) 117:1379–90.10.1160/TH16-10-0784
96
MertenMPakalaRThiagarajanPBenedictCR. Platelet microparticles promote platelet interaction with subendothelial matrix in a glycoprotein IIb/IIIa-dependent mechanism. Circulation (1999) 99:2577–82.10.1161/01.CIR.99.19.2577
97
SuadesRPadroTVilahurGBadimonL. Circulating and platelet-derived microparticles in human blood enhance thrombosis on atherosclerotic plaques. Thromb Haemost (2012) 108:1208–19.10.1160/TH12-07-0486
98
MauseSF. Platelet microparticles: reinforcing the hegemony of platelets in atherothrombosis. Thromb Haemost (2013) 109:5–6.10.1160/TH12-11-0817
99
SuadesRPadroTVilahurGMartin-YusteVSabateMSans-RoselloJet alGrowing thrombi release increased levels of CD235a(+) microparticles and decreased levels of activated platelet-derived microparticles. Validation in ST-elevation myocardial infarction patients. J Thromb Haemost (2015) 13:1776–86.10.1111/jth.13065
100
BerckmansRJNieuwlandRBoingANRomijnFPHackCESturkA. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost (2001) 85(4):639–46.
101
ZwickerJITrenorCCIIIFurieBCFurieB. Tissue factor-bearing microparticles and thrombus formation. Arterioscler Thromb Vasc Biol (2011) 31:728–33.10.1161/ATVBAHA.109.200964
102
BurnierLFontanaPKwakBRAngelillo-ScherrerA. Cell-derived microparticles in haemostasis and vascular medicine. Thromb Haemost (2009) 101(3):439–51.10.1160/TH08-08-0521
103
TothBNikolajekKRankANieuwlandRLohsePPihuschVet alGender-specific and menstrual cycle dependent differences in circulating microparticles. Platelets (2007) 18:515–21.10.1080/09537100701525843
104
RobertSPonceletPLacroixRArnaudLGiraudoLHauchardAet alStandardization of platelet-derived microparticle counting using calibrated beads and a Cytomics FC500 routine flow cytometer: a first step towards multicenter studies?J Thromb Haemost (2009) 7:190–7.10.1111/j.1538-7836.2008.03200.x
105
van der ZeePMBiroEKoYDe WinterRJHackCESturkAet alP-selectin- and CD63-exposing platelet microparticles reflect platelet activation in peripheral arterial disease and myocardial infarction. Clin Chem (2006) 52:657–64.10.1373/clinchem.2005.057414
106
BretelleFSabatierFDesprezDCamoinLGrunebaumLCombesVet alCirculating microparticles: a marker of procoagulant state in normal pregnancy and pregnancy complicated by preeclampsia or intrauterine growth restriction. Thromb Haemost (2003) 89(3):486–92.
107
ChaarVRomanaMTripetteJBroquereCHuisseMGHueOet alEffect of strenuous physical exercise on circulating cell-derived microparticles. Clin Hemorheol Microcirc (2011) 47:15–25.10.3233/CH-2010-1361
108
SossdorfMOttoGPClausRAGabrielHHLöscheW. Cell-derived microparticles promote coagulation after moderate exercise. Med Sci Sports Exerc (2011) 43:1169–76.10.1249/MSS.0b013e3182068645
109
MaruyamaKKadonoTMorishitaE. Plasma levels of platelet-derived microparticles are increased after anaerobic exercise in healthy subjects. J Atheroscler Thromb (2012) 19:585–7.10.5551/jat.11791
110
TushuizenMENieuwlandRSchefferPGSturkAHeineRJDiamantM. Two consecutive high-fat meals affect endothelial-dependent vasodilation, oxidative stress and cellular microparticles in healthy men. J Thromb Haemost (2006) 4:1003–10.10.1111/j.1538-7836.2006.01914.x
111
EnjetiAKAriyarajahAD’CrusASeldonMLinczLF. Circulating microvesicle number, function and small RNA content vary with age, gender, smoking status, lipid and hormone profiles. Thromb Res (2017) 156:65–72.10.1016/j.thromres.2017.04.019
112
SuadesRPadroTAlonsoRMataPBadimonL. High levels of TSP1+/CD142+ platelet-derived microparticles characterise young patients with high cardiovascular risk and subclinical atherosclerosis. Thromb Haemost (2015) 114:1310–21.10.1160/TH15-04-0325
113
SuadesRPadroTAlonsoRLopez-MirandaJMataPBadimonL. Circulating CD45+/CD3+ lymphocyte-derived microparticles map lipid-rich atherosclerotic plaques in familial hypercholesterolaemia patients. Thromb Haemost (2014) 111:111–21.10.1160/TH13-07-0612
114
GoichotBGrunebaumLDesprezDVinzioSMeyerLSchliengerJLet alCirculating procoagulant microparticles in obesity. Diabetes Metab (2006) 32:82–5.10.1016/S1262-3636(07)70251-3
115
HeissCAmabileNLeeACRealWMSchickSFLaoDet alBrief secondhand smoke exposure depresses endothelial progenitor cells activity and endothelial function: sustained vascular injury and blunted nitric oxide production. J Am Coll Cardiol (2008) 51:1760–71.10.1016/j.jacc.2008.01.040
116
GordonCGudiKKrauseASackrowitzRHarveyBGStrulovici-BarelYet alCirculating endothelial microparticles as a measure of early lung destruction in cigarette smokers. Am J Respir Crit Care Med (2011) 184(2):224–32.10.1164/rccm.201012-2061OC
117
LiJZhangYLiuYDaiXLiWCaiXet alMicrovesicle-mediated transfer of microRNA-150 from monocytes to endothelial cells promotes angiogenesis. J Biol Chem (2013) 288:23586–96.10.1074/jbc.M113.489302
118
JayachandranMLitwillerRDLahrBDBaileyKROwenWGMulvaghSLet alAlterations in platelet function and cell-derived microvesicles in recently menopausal women: relationship to metabolic syndrome and atherogenic risk. J Cardiovasc Transl Res (2011) 4:811–22.10.1007/s12265-011-9296-9
119
SabatierFDarmonPHugelBCombesVSanmarcoMVelutJGet alType 1 and type 2 diabetic patients display different patterns of cellular microparticles. Diabetes (2002) 51:2840–5.10.2337/diabetes.51.9.2840
120
NomuraSShouzuAOmotoSNishikawaMIwasakaTFukuharaS. Activated platelet and oxidized LDL induce endothelial membrane vesiculation: clinical significance of endothelial cell-derived microparticles in patients with type 2 diabetes. Clin Appl Thromb Hemost (2004) 10:205–15.10.1177/107602960401000302
121
NomuraSTakahashiNInamiNKajiuraTYamadaKNakamoriHet alProbucol and ticlopidine: effect on platelet and monocyte activation markers in hyperlipidemic patients with and without type 2 diabetes. Atherosclerosis (2004) 174:329–35.10.1016/j.atherosclerosis.2004.01.027
122
ShouzuANomuraSOmotoSHayakawaTNishikawaMIwasakaT. Effect of ticlopidine on monocyte-derived microparticles and activated platelet markers in diabetes mellitus. Clin Appl Thromb Hemost (2004) 10:167–73.10.1177/107602960401000207
123
KogaHSugiyamaSKugiyamaKWatanabeKFukushimaHTanakaTet alElevated levels of VE-cadherin-positive endothelial microparticles in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol (2005) 45:1622–30.10.1016/j.jacc.2005.02.047
124
OmotoSNomuraSShouzuAHayakawaTShimizuHMiyakeYet alSignificance of platelet-derived microparticles and activated platelets in diabetic nephropathy. Nephron (1999) 81:271–7.10.1159/000045292
125
DiamantMNieuwlandRPabloRFSturkASmitJWRadderJK. Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation (2002) 106:2442–7.10.1161/01.CIR.0000036596.59665.C6
126
KogaHSugiyamaSKugiyamaKFukushimaHWatanabeKSakamotoTet alElevated levels of remnant lipoproteins are associated with plasma platelet microparticles in patients with type-2 diabetes mellitus without obstructive coronary artery disease. Eur Heart J (2006) 27:817–23.10.1093/eurheartj/ehi746
127
BernardSLoffroyRSerusclatABousselLBonnefoyEThevenonCet alIncreased levels of endothelial microparticles CD144 (VE-Cadherin) positives in type 2 diabetic patients with coronary noncalcified plaques evaluated by multidetector computed tomography (MDCT). Atherosclerosis (2009) 203:429–35.10.1016/j.atherosclerosis.2008.07.039
128
OgataNNomuraSShouzuAImaizumiMArichiMMatsumuraM. Elevation of monocyte-derived microparticles in patients with diabetic retinopathy. Diabetes Res Clin Pract (2006) 73:241–8.10.1016/j.diabres.2006.01.014
129
GunduzZDursunITulparSBastugFBaykanAYikilmazAet alIncreased endothelial microparticles in obese and overweight children. J Pediatr Endocrinol Metab (2012) 25:1111–7.10.1515/jpem-2012-0194
130
MurakamiTHorigomeHTanakaKNakataYOhkawaraKKatayamaYet alImpact of weight reduction on production of platelet-derived microparticles and fibrinolytic parameters in obesity. Thromb Res (2007) 119:45–53.10.1016/j.thromres.2005.12.013
131
StepanianABourguignatLHennouSCoupayeMHajageDSalomonLet alMicroparticle increase in severe obesity: not related to metabolic syndrome and unchanged after massive weight loss. Obesity (Silver Spring) (2013) 21:2236–43.10.1002/oby.20365
132
ChengVKashyapSRSchauerPRKirwanJPMccraeKR. Restoration of glycemic control in patients with type 2 diabetes mellitus after bariatric surgery is associated with reduction in microparticles. Surg Obes Relat Dis (2013) 9:207–12.10.1016/j.soard.2011.09.026
133
NomuraSKanazawaSFukuharaS. Effects of efonidipine on platelet and monocyte activation markers in hypertensive patients with and without type 2 diabetes mellitus. J Hum Hypertens (2002) 16:539–47.10.1038/sj.jhh.1001447
134
PrestonRAJyWJimenezJJMauroLMHorstmanLLValleMet alEffects of severe hypertension on endothelial and platelet microparticles. Hypertension (2003) 41:211–7.10.1161/01.HYP.0000049760.15764.2D
135
NomuraSShouzuAOmotoSNishikawaMIwasakaT. Effects of losartan and simvastatin on monocyte-derived microparticles in hypertensive patients with and without type 2 diabetes mellitus. Clin Appl Thromb Hemost (2004) 10:133–41.10.1177/107602960401000203
136
FerreiraACPeterAAMendezAJJimenezJJMauroLMChirinosJAet alPostprandial hypertriglyceridemia increases circulating levels of endothelial cell microparticles. Circulation (2004) 110:3599–603.10.1161/01.CIR.0000148820.55611.6B
137
ArteagaRBChirinosJASorianoAOJyWHorstmanLJimenezJJet alEndothelial microparticles and platelet and leukocyte activation in patients with the metabolic syndrome. Am J Cardiol (2006) 98:70–4.10.1016/j.amjcard.2006.01.054
138
UebaTHazeTSugiyamaMHiguchiMAsayamaHKaritaniYet alLevel, distribution and correlates of platelet-derived microparticles in healthy individuals with special reference to the metabolic syndrome. Thromb Haemost (2008) 100(2):280–5.10.1160/TH07-11-0668
139
HelalODefoortCRobertSMarinCLesavreNLopez-MirandaJet alIncreased levels of microparticles originating from endothelial cells, platelets and erythrocytes in subjects with metabolic syndrome: relationship with oxidative stress. Nutr Metab Cardiovasc Dis (2011) 21:665–71.10.1016/j.numecd.2010.01.004
140
AmabileNChengSRenardJMLarsonMGGhorbaniAMccabeEet alAssociation of circulating endothelial microparticles with cardiometabolic risk factors in the Framingham Heart Study. Eur Heart J (2014) 35:2972–9.10.1093/eurheartj/ehu153
141
AndoMIwataAOzekiYTsuchiyaKAkibaTNiheiH. Circulating platelet-derived microparticles with procoagulant activity may be a potential cause of thrombosis in uremic patients. Kidney Int (2002) 62:1757–63.10.1046/j.1523-1755.2002.00627.x
142
NozakiTSugiyamaSKogaHSugamuraKOhbaKMatsuzawaYet alSignificance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease. J Am Coll Cardiol (2009) 54:601–8.10.1016/j.jacc.2009.05.022
143
JayachandranMLitwillerRDOwenWGHeitJABehrenbeckTMulvaghSLet alCharacterization of blood borne microparticles as markers of premature coronary calcification in newly menopausal women. Am J Physiol Heart Circ Physiol (2008) 295:H931–8.10.1152/ajpheart.00193.2008
144
ZeigerFStephanSHoheiselGPfeifferDRuehlmannCKokschM. P-Selectin expression, platelet aggregates, and platelet-derived microparticle formation are increased in peripheral arterial disease. Blood Coagul Fibrinolysis (2000) 11(8):723–8.10.1097/00001721-200012000-00005
145
ChironiGSimonAHugelBDel PinoMGariepyJFreyssinetJMet alCirculating leukocyte-derived microparticles predict subclinical atherosclerosis burden in asymptomatic subjects. Arterioscler Thromb Vasc Biol (2006) 26:2775–80.10.1161/01.ATV.0000249639.36915.04
146
Bernal-MizrachiLJyWJimenezJJPastorJMauroLMHorstmanLLet alHigh levels of circulating endothelial microparticles in patients with acute coronary syndromes. Am Heart J (2003) 145:962–70.10.1016/S0002-8703(03)00103-0
147
SinningJMLoschJWalentaKBohmMNickenigGWernerN. Circulating CD31+/Annexin V+ microparticles correlate with cardiovascular outcomes. Eur Heart J (2011) 32:2034–41.10.1093/eurheartj/ehq478
148
JansenFYangXProebstingSHoelscherMPrzybillaDBaumannKet alMicroRNA expression in circulating microvesicles predicts cardiovascular events in patients with coronary artery disease. J Am Heart Assoc (2014) 3:e001249.10.1161/JAHA.114.001249
149
MallatZBenamerHHugelBBenessianoJStegPGFreyssinetJMet alElevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation (2000) 101:841–3.10.1161/01.CIR.101.8.841
150
NomuraSUehataSSaitoSOsumiKOzekiYKimuraY. Enzyme immunoassay detection of platelet-derived microparticles and RANTES in acute coronary syndrome. Thromb Haemost (2003) 89(3):506–12.
151
Bernal-MizrachiLJyWFierroCMacdonoughRVelazquesHAPurowJet alEndothelial microparticles correlate with high-risk angiographic lesions in acute coronary syndromes. Int J Cardiol (2004) 97:439–46.10.1016/j.ijcard.2003.10.029
152
LiXCongH. Platelet-derived microparticles and the potential of glycoprotein IIb/IIIa antagonists in treating acute coronary syndrome. Tex Heart Inst J (2009) 36(2):134–9.
153
D’AlessandraYDevannaPLimanaFStrainoSDi CarloABrambillaPGet alCirculating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J (2010) 31:2765–73.10.1093/eurheartj/ehq167
154
UebaTNomuraSInamiNNishikawaTKajiwaraMIwataRet alPlasma level of platelet-derived microparticles is associated with coronary heart disease risk score in healthy men. J Atheroscler Thromb (2010) 17:342–9.10.5551/jat.2964
155
SuadesRPadroTCrespoJRamaiolaIMartin-YusteVSabateMet alCirculating microparticle signature in coronary and peripheral blood of ST elevation myocardial infarction patients in relation to pain-to-PCI elapsed time. Int J Cardiol (2016) 202:378–87.10.1016/j.ijcard.2015.09.011
156
Chiva-BlanchGLaakeKMyhrePBratsethVArnesenHSolheimSet alPlatelet-, monocyte-derived and tissue factor-carrying circulating microparticles are related to acute myocardial infarction severity. PLoS One (2017) 12:e0172558.10.1371/journal.pone.0172558
157
LeeYJJyWHorstmanLLJananiaJReyesYKelleyREet alElevated platelet microparticles in transient ischemic attacks, lacunar infarcts, and multiinfarct dementias. Thromb Res (1993) 72:295–304.10.1016/0049-3848(93)90138-E
158
SimakJGeldermanMPYuHWrightVBairdAE. Circulating endothelial microparticles in acute ischemic stroke: a link to severity, lesion volume and outcome. J Thromb Haemost (2006) 4:1296–302.10.1111/j.1538-7836.2006.01911.x
159
JungKHChuKLeeSTParkHKBahnJJKimDHet alCirculating endothelial microparticles as a marker of cerebrovascular disease. Ann Neurol (2009) 66:191–9.10.1002/ana.21681
160
LukasikMRozalskiMLuzakBMichalakSKozubskiWWatalaC. Platelet activation and reactivity in the convalescent phase of ischaemic stroke. Thromb Haemost (2010) 103:644–50.10.1160/TH09-08-0599
161
KimSJMoonGJChoYHKangHYHyungNKKimDet alCirculating mesenchymal stem cells microparticles in patients with cerebrovascular disease. PLoS One (2012) 7:e37036.10.1371/journal.pone.0037036
162
Chiva-BlanchGSuadesRCrespoJPenaEPadroTJimenez-XarrieEet alMicroparticle shedding from neural progenitor cells and vascular compartment cells is increased in ischemic stroke. PLoS One (2016) 11:e0148176.10.1371/journal.pone.0148176
163
LacknerPDietmannABeerRFischerMBroessnerGHelbokRet alCellular microparticles as a marker for cerebral vasospasm in spontaneous subarachnoid hemorrhage. Stroke (2010) 41:2353–7.10.1161/STROKEAHA.110.584995
164
MichelsenAENotøATBrodinEMathiesenEBBrosstadFHansenJB. Elevated levels of platelet microparticles in carotid atherosclerosis and during the postprandial state. Thromb Res (2009) 123:881–6.10.1016/j.thromres.2008.10.016
165
Chiva-BlanchGSuadesRCrespoJVilahurGArderiuGPadroTet alCD3(+)/CD45(+) and SMA-alpha(+) circulating microparticles are increased in individuals at high cardiovascular risk who will develop a major cardiovascular event. Int J Cardiol (2016) 208:147–9.10.1016/j.ijcard.2016.01.211
166
Chiva-BlanchGBratsethVRitschelVAndersenGOHalvorsenSEritslandJet alMonocyte-derived circulating microparticles (CD14+, CD14+/CD11b+ and CD14+/CD142+) are related to long-term prognosis for cardiovascular mortality in STEMI patients. Int J Cardiol (2017) 227:876–81.10.1016/j.ijcard.2016.11.302
167
WalshKBCamposBHartKThakarCAdeoyeO. M2 monocyte microparticles are increased in intracerebral hemorrhage. J Stroke Cerebrovasc Dis (2017) 26(10):2369–75.10.1016/j.jstrokecerebrovasdis.2017.05.027
168
CarmelietPJainRK. Molecular mechanisms and clinical applications of angiogenesis. Nature (2011) 473:298–307.10.1038/nature10144
169
PircherATrepsLBodrugNCarmelietP. Endothelial cell metabolism: a novel player in atherosclerosis? Basic principles and therapeutic opportunities. Atherosclerosis (2016) 253:247–57.10.1016/j.atherosclerosis.2016.08.011
170
Juan-BabotJOMartinez-GonzalezJBerrozpeMBadimonL. [Neovascularization in human coronary arteries with lesions of different severity]. Rev Esp Cardiol (2003) 56:978–86.10.1016/S0300-8932(03)76995-4
171
BeltingMChristiansonHC. Role of exosomes and microvesicles in hypoxia-associated tumour development and cardiovascular disease. J Intern Med (2015) 278:251–63.10.1111/joim.12393
172
BrillADashevskyORivoJGozalYVaronD. Platelet-derived microparticles induce angiogenesis and stimulate post-ischemic revascularization. Cardiovasc Res (2005) 67:30–8.10.1016/j.cardiores.2005.04.007
173
MezentsevAMerksRMO’RiordanEChenJMendelevNGoligorskyMSet alEndothelial microparticles affect angiogenesis in vitro: role of oxidative stress. Am J Physiol Heart Circ Physiol (2005) 289:H1106–14.10.1152/ajpheart.00265.2005
174
SoletiRBenameurTPorroCPanaroMAAndriantsitohainaRMartinezMC. Microparticles harboring Sonic Hedgehog promote angiogenesis through the upregulation of adhesion proteins and proangiogenic factors. Carcinogenesis (2009) 30:580–8.10.1093/carcin/bgp030
175
BenameurTSoletiRPorroCAndriantsitohainaRMartinezMC. Microparticles carrying Sonic hedgehog favor neovascularization through the activation of nitric oxide pathway in mice. PLoS One (2010) 5:e12688.10.1371/journal.pone.0012688
176
OuZJChangFJLuoDLiaoXLWangZPZhangXet alEndothelium-derived microparticles inhibit angiogenesis in the heart and enhance the inhibitory effects of hypercholesterolemia on angiogenesis. Am J Physiol Endocrinol Metab (2011) 300:E661–8.10.1152/ajpendo.00611.2010
177
TodorovaDSimonciniSLacroixRSabatierFDignat-GeorgeF. Extracellular vesicles in angiogenesis. Circ Res (2017) 120:1658–73.10.1161/CIRCRESAHA.117.309681
178
OhtsukaMSasakiKUenoTSekiRNakayoshiTKoiwayaHet alPlatelet-derived microparticles augment the adhesion and neovascularization capacities of circulating angiogenic cells obtained from atherosclerotic patients. Atherosclerosis (2013) 227:275–82.10.1016/j.atherosclerosis.2013.01.040
179
HayonYDashevskyOShaiEBrillAVaronDLekerRR. Platelet microparticles induce angiogenesis and neurogenesis after cerebral ischemia. Curr Neurovasc Res (2012) 9:185–92.10.2174/156720212801619018
180
ShanLYLiJZZuLYNiuCGFerroAZhangYDet alPlatelet-derived microparticles are implicated in remote ischemia conditioning in a rat model of cerebral infarction. CNS Neurosci Ther (2013) 19:917–25.10.1111/cns.12199
181
KimHKSongKSChungJHLeeKRLeeSN. Platelet microparticles induce angiogenesis in vitro. Br J Haematol (2004) 124:376–84.10.1046/j.1365-2141.2003.04773.x
182
MauseSFRitzelELiehnEAHristovMBidzhekovKMuller-NewenGet alPlatelet microparticles enhance the vasoregenerative potential of angiogenic early outgrowth cells after vascular injury. Circulation (2010) 122:495–506.10.1161/CIRCULATIONAHA.109.909473
183
LeroyerASEbrahimianTGCochainCRecaldeABlanc-BrudeOMeesBet alMicroparticles from ischemic muscle promotes postnatal vasculogenesis. Circulation (2009) 119:2808–17.10.1161/CIRCULATIONAHA.108.816710
184
LacroixRSabatierFMialheABasireAPannellRBorghiHet alActivation of plasminogen into plasmin at the surface of endothelial microparticles: a mechanism that modulates angiogenic properties of endothelial progenitor cells in vitro. Blood (2007) 110:2432–9.10.1182/blood-2007-02-069997
185
SunCFengSBCaoZWBeiJJChenQZhaoWBet alUp-regulated expression of matrix metalloproteinases in endothelial cells mediates platelet microvesicle-induced angiogenesis. Cell Physiol Biochem (2017) 41:2319–32.10.1159/000475651
186
LeroyerASRautouPESilvestreJSCastierYLesecheGDevueCet alCD40 ligand+ microparticles from human atherosclerotic plaques stimulate endothelial proliferation and angiogenesis a potential mechanism for intraplaque neovascularization. J Am Coll Cardiol (2008) 52:1302–11.10.1016/j.jacc.2008.07.032
187
MerjanehMLangloisALarochelleSCloutierCBRicard-BlumSMoulinVJ. Pro-angiogenic capacities of microvesicles produced by skin wound myofibroblasts. Angiogenesis (2017) 20:385–98.10.1007/s10456-017-9554-9
188
DeregibusMCCantaluppiVCalogeroRLo IaconoMTettaCBianconeLet alEndothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. Blood (2007) 110:2440–8.10.1182/blood-2007-03-078709
189
BianSZhangLDuanLWangXMinYYuH. Extracellular vesicles derived from human bone marrow mesenchymal stem cells promote angiogenesis in a rat myocardial infarction model. J Mol Med (Berl) (2014) 92:387–97.10.1007/s00109-013-1110-5
190
DoeppnerTRHerzJGorgensASchlechterJLudwigAKRadtkeSet alExtracellular vesicles improve post-stroke neuroregeneration and prevent postischemic immunosuppression. Stem Cells Transl Med (2015) 4:1131–43.10.5966/sctm.2015-0078
191
ZhangHCLiuXBHuangSBiXYWangHXXieLXet alMicrovesicles derived from human umbilical cord mesenchymal stem cells stimulated by hypoxia promote angiogenesis both in vitro and in vivo. Stem Cells Dev (2012) 21:3289–97.10.1089/scd.2012.0095
192
ZouXGuDXingXChengZGongDZhangGet alHuman mesenchymal stromal cell-derived extracellular vesicles alleviate renal ischemic reperfusion injury and enhance angiogenesis in rats. Am J Transl Res (2016) 8(10):4289–99.
193
ProkopiMPulaGMayrUDevueCGallagherJXiaoQet alProteomic analysis reveals presence of platelet microparticles in endothelial progenitor cell cultures. Blood (2009) 114:723–32.10.1182/blood-2009-02-205930
194
VaronDHayonYDashevskyOShaiE. Involvement of platelet derived microparticles in tumor metastasis and tissue regeneration. Thromb Res (2012) 130(Suppl 1):S98–9.10.1016/j.thromres.2012.08.289
195
AgouniAMostefaiHAPorroCCarusioNFavreJRichardVet alSonic hedgehog carried by microparticles corrects endothelial injury through nitric oxide release. FASEB J (2007) 21:2735–41.10.1096/fj.07-8079com
196
GullerSTangZMaYYDi SantoSSagerRSchneiderH. Protein composition of microparticles shed from human placenta during placental perfusion: potential role in angiogenesis and fibrinolysis in preeclampsia. Placenta (2011) 32:63–9.10.1016/j.placenta.2010.10.011
197
YangCMwaikamboBRZhuTGagnonCLafleurJSeshadriSet alLymphocytic microparticles inhibit angiogenesis by stimulating oxidative stress and negatively regulating VEGF-induced pathways. Am J Physiol Regul Integr Comp Physiol (2008) 294:R467–76.10.1152/ajpregu.00432.2007
198
RamakrishnanDPHajj-AliRAChenYSilversteinRL. Extracellular vesicles activate a CD36-dependent signaling pathway to inhibit microvascular endothelial cell migration and tube formation. Arterioscler Thromb Vasc Biol (2016) 36:534–44.10.1161/ATVBAHA.115.307085
199
LopatinaTBrunoSTettaCKalininaNPortaMCamussiG. Platelet-derived growth factor regulates the secretion of extracellular vesicles by adipose mesenchymal stem cells and enhances their angiogenic potential. Cell Commun Signal (2014) 12:26.10.1186/1478-811X-12-26
200
BoopathyGTKKulkarniMHoSYBoeyAChuaEWMBarathiVAet alCavin-2 regulates the activity and stability of endothelial nitric oxide synthase (eNOS) in angiogenesis. J Biol Chem (2017) 292(43):17760–76.10.1074/jbc.M117.794743
201
TuruMMSlevinMMatouSWestDRodriguezCLuqueAet alC-reactive protein exerts angiogenic effects on vascular endothelial cells and modulates associated signalling pathways and gene expression. BMC Cell Biol (2008) 9:47.10.1186/1471-2121-9-47
202
HabersbergerJStrangFScheichlAHtunNBasslerNMerivirtaRMet alCirculating microparticles generate and transport monomeric C-reactive protein in patients with myocardial infarction. Cardiovasc Res (2012) 96:64–72.10.1093/cvr/cvs237
203
BelikDTsangHWhartonJHowardLBernabeuCWojciak-StothardB. Endothelium-derived microparticles from chronically thromboembolic pulmonary hypertensive patients facilitate endothelial angiogenesis. J Biomed Sci (2016) 23:4.10.1186/s12929-016-0224-9
204
WilhelmENGonzalez-AlonsoJParrisCRakobowchukM. Exercise intensity modulates the appearance of circulating microvesicles with proangiogenic potential upon endothelial cells. Am J Physiol Heart Circ Physiol (2016) 311:H1297–310.10.1152/ajpheart.00516.2016
205
JainMBhosaleVTripathiDSinghHPalNHanifKet alAntihypertensive drugs aliskiren, nebivolol, and olmesartan reduce hypertension by reducing endothelial microparticles and regulating angiogenesis. J Cardiovasc Pharmacol (2017) 70:176–83.10.1097/FJC.0000000000000503
206
KangTJonesTMNaddellCBacanamwoMCalvertJWThompsonWEet alAdipose-derived stem cells induce angiogenesis via microvesicle transport of miRNA-31. Stem Cells Transl Med (2016) 5:440–50.10.5966/sctm.2015-0177
207
RanghinoACantaluppiVGrangeCVitilloLFopFBianconeLet alEndothelial progenitor cell-derived microvesicles improve neovascularization in a murine model of hindlimb ischemia. Int J Immunopathol Pharmacol (2012) 25:75–85.10.1177/039463201202500110
208
CantaluppiVBianconeLFiglioliniFBeltramoSMedicaDDeregibusMCet alMicrovesicles derived from endothelial progenitor cells enhance neoangiogenesis of human pancreatic islets. Cell Transplant (2012) 21:1305–20.10.3727/096368911X627534
209
LombardoGDentelliPTogliattoGRossoAGiliMGalloSet alActivated Stat5 trafficking via endothelial cell-derived extracellular vesicles controls IL-3 pro-angiogenic paracrine action. Sci Rep (2016) 6:25689.10.1038/srep25689
210
ZerneckeABidzhekovKNoelsHShagdarsurenEGanLDeneckeBet alDelivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal (2009) 2:ra81.10.1126/scisignal.2000610
211
RakJMilsomCMayLKlementPYuJ. Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. Semin Thromb Hemost (2006) 32:54–70.10.1055/s-2006-933341
212
ArderiuGPenaEAledoRBadimonL. Tissue factor-Akt signaling triggers microvessel formation. J Thromb Haemost (2012) 10:1895–905.10.1111/j.1538-7836.2012.04848.x
213
ArderiuGEspinosaSPenaECrespoJAledoRBogdanovVYet alTissue factor variants induce monocyte transformation and transdifferentiation into endothelial cell-like cells. J Thromb Haemost (2017) 15(8):1689–703.10.1111/jth.13751
214
SvenssonKJKucharzewskaPChristiansonHCSkoldSLofstedtTJohanssonMCet alHypoxia triggers a proangiogenic pathway involving cancer cell microvesicles and PAR-2-mediated heparin-binding EGF signaling in endothelial cells. Proc Natl Acad Sci U S A (2011) 108:13147–52.10.1073/pnas.1104261108
215
CollierMEEttelaieC. Induction of endothelial cell proliferation by recombinant and microparticle-tissue factor involves beta1-integrin and extracellular signal regulated kinase activation. Arterioscler Thromb Vasc Biol (2010) 30:1810–7.10.1161/ATVBAHA.110.211854
216
ArderiuGPenaEBadimonL. Angiogenic microvascular endothelial cells release microparticles rich in tissue factor that promotes postischemic collateral vessel formation. Arterioscler Thromb Vasc Biol (2015) 35:348–57.10.1161/ATVBAHA.114.303927
217
MartinezMCAndriantsitohainaR. Microparticles in angiogenesis: therapeutic potential. Circ Res (2011) 109:110–9.10.1161/CIRCRESAHA.110.233049
218
GravesLEAriztiaEVNavariJRMatzelHJStackMSFishmanDA. Proinvasive properties of ovarian cancer ascites-derived membrane vesicles. Cancer Res (2004) 64:7045–9.10.1158/0008-5472.CAN-04-1800
219
Janowska-WieczorekAWysoczynskiMKijowskiJMarquez-CurtisLMachalinskiBRatajczakJet alMicrovesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer (2005) 113:752–60.10.1002/ijc.20657
220
TarabolettiGD’AscenzoSGiustiIMarchettiDBorsottiPMillimaggiDet alBioavailability of VEGF in tumor-shed vesicles depends on vesicle burst induced by acidic pH. Neoplasia (2006) 8:96–103.10.1593/neo.05583
221
Al-NedawiKMeehanBKerbelRSAllisonACRakJ. Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proc Natl Acad Sci U S A (2009) 106:3794–9.10.1073/pnas.0804543106
222
YangCGagnonCHouXHardyP. Low density lipoprotein receptor mediates anti-VEGF effect of lymphocyte T-derived microparticles in Lewis lung carcinoma cells. Cancer Biol Ther (2010) 10:448–56.10.4161/cbt.10.5.12533
223
YangCXiongWQiuQShaoZHamelDTahiriHet alRole of receptor-mediated endocytosis in the antiangiogenic effects of human T lymphoblastic cell-derived microparticles. Am J Physiol Regul Integr Comp Physiol (2012) 302:R941–9.10.1152/ajpregu.00527.2011
224
ZhuangGWuXJiangZKasmanIYaoJGuanYet alTumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J (2012) 31:3513–23.10.1038/emboj.2012.183
225
ZhangHBaiMDengTLiuRWangXQuYet alCell-derived microvesicles mediate the delivery of miR-29a/c to suppress angiogenesis in gastric carcinoma. Cancer Lett (2016) 375:331–9.10.1016/j.canlet.2016.03.026
226
FengQZhangCLumDDrusoJEBlankBWilsonKFet alA class of extracellular vesicles from breast cancer cells activates VEGF receptors and tumour angiogenesis. Nat Commun (2017) 8:14450.10.1038/ncomms14450
227
HuaitongXYuanyongFYueqinTPengZWeiSKaiS. Microvesicles releasing by oral cancer cells enhance endothelial cell angiogenesis via Shh/RhoA signaling pathway. Cancer Biol Ther (2017) 18(10):783–91.10.1080/15384047.2017.1373213
228
TrepsLPerretREdmondSRicardDGavardJ. Glioblastoma stem-like cells secrete the pro-angiogenic VEGF-A factor in extracellular vesicles. J Extracell Vesicles (2017) 6:1359479.10.1080/20013078.2017.1359479
229
EstruchRRosESalas-SalvadoJCovasMICorellaDArosFet alPrimary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med (2013) 368:1279–90.10.1056/NEJMoa1200303
230
Chiva-BlanchGCrespoJSuadesRArderiuGPadroTVilahurGet alCD142+/CD61+, CD146+ and CD45+ microparticles predict cardiovascular events in high risk patients following a Mediterranean diet supplemented with nuts. Thromb Haemost (2016) 116:103–14.10.1160/TH16-02-0130
231
NomuraSShouzuAOmotoSHayakawaTKagawaHNishikawaMet alEffect of cilostazol on soluble adhesion molecules and platelet-derived microparticles in patients with diabetes. Thromb Haemost (1998) 80:388–92.
232
NomuraSOmotoSYokoiTFujitaSOzasaREguchiNet alEffects of miglitol in platelet-derived microparticle, adiponectin, and selectin level in patients with type 2 diabetes mellitus. Int J Gen Med (2011) 4:539–45.10.2147/IJGM.S22115
233
MobarrezFHeSBroijersenAWiklundBAntovicAAntovicJet alAtorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIIa on platelet-derived microparticles in patients with peripheral arterial occlusive disease. Thromb Haemost (2011) 106:344–52.10.1160/TH10-12-0810
234
WangJMYangZXuMGChenLWangYSuCet alBerberine-induced decline in circulating CD31+/CD42- microparticles is associated with improvement of endothelial function in humans. Eur J Pharmacol (2009) 614:77–83.10.1016/j.ejphar.2009.04.037
235
ChengFWangYLiJSuCWuFXiaWHet alBerberine improves endothelial function by reducing endothelial microparticles-mediated oxidative stress in humans. Int J Cardiol (2013) 167:936–42.10.1016/j.ijcard.2012.03.090
236
ZuLRenCPanBZhouBZhouENiuCet alEndothelial microparticles after antihypertensive and lipid-lowering therapy inhibit the adhesion of monocytes to endothelial cells. Int J Cardiol (2016) 202:756–9.10.1016/j.ijcard.2015.10.035
237
GotoSTamuraNLiMHandaMIkedaYHandaSet alDifferent effects of various anti-GPIIb-IIIa agents on shear-induced platelet activation and expression of procoagulant activity. J Thromb Haemost (2003) 1:2022–30.10.1046/j.1538-7836.2003.00349.x
238
MorelOHugelBJeselLMallatZLanzaFDouchetMPet alCirculating procoagulant microparticles and soluble GPV in myocardial infarction treated by primary percutaneous transluminal coronary angioplasty. A possible role for GPIIb-IIIa antagonists. J Thromb Haemost (2004) 2:1118–26.10.1111/j.1538-7836.2004.00805.x
239
JudgeHMBucklandRJSugidachiAJakubowskiJAStoreyRF. Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function. Thromb Haemost (2010) 103:1210–7.10.1160/TH09-11-0770
240
FrancaCNPinheiroLFIzarMCBrunialtiMKSalomaoRBiancoHTet alEndothelial progenitor cell mobilization and platelet microparticle release are influenced by clopidogrel plasma levels in stable coronary artery disease. Circ J (2012) 76:729–36.10.1253/circj.CJ-11-1145
241
BulutDBeckerVMuggeA. Acetylsalicylate reduces endothelial and platelet-derived microparticles in patients with coronary artery disease. Can J Physiol Pharmacol (2011) 89:239–44.10.1139/y11-013
242
SkeppholmMMobarrezFMalmqvistKWallenH. Platelet-derived microparticles during and after acute coronary syndrome. Thromb Haemost (2012) 107:1122–9.10.1160/TH11-11-0779
243
LubsczykBKollarsMHronGKyrlePAWeltermannAGartnerV. Low dose acetylsalicylic acid and shedding of microparticles in vivo in humans. Eur J Clin Invest (2010) 40:477–82.10.1111/j.1365-2362.2010.02299.x
244
Chiva-BlanchGSuadesRPadroTVilahurGPenaEYbarraJet alMicroparticle shedding by erythrocytes, monocytes and vascular smooth muscular cells is reduced by aspirin in diabetic patients. Rev Esp Cardiol (Engl Ed) (2016) 69(7):672–80.10.1016/j.rec.2015.12.033
245
LabiosMMartinezMGabrielFGuiralVMunozAAznarJ. Effect of eprosartan on cytoplasmic free calcium mobilization, platelet activation, and microparticle formation in hypertension. Am J Hypertens (2004) 17:757–63.10.1016/j.amjhyper.2004.05.010
246
NomuraSInamiNKimuraYOmotoSShouzuANishikawaMet alEffect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus. J Hum Hypertens (2007) 21:38–44.10.1038/sj.jhh.1002100
247
MorelOJeselLHugelBDouchetMPZupanMChauvinMet alProtective effects of vitamin C on endothelium damage and platelet activation during myocardial infarction in patients with sustained generation of circulating microparticles. J Thromb Haemost (2003) 1:171–7.10.1046/j.1538-7836.2003.00010.x
248
KagawaHNomuraSNagahamaMOzakiYFukuharaS. Effect of bezafibrate on soluble adhesion molecules and platelet activation markers in patients with connective tissue diseases and secondary hyperlipidemia. Clin Appl Thromb Hemost (2001) 7:153–7.10.1177/107602960100700213
249
EspositoKCiotolaMGiuglianoD. Pioglitazone reduces endothelial microparticles in the metabolic syndrome. Arterioscler Thromb Vasc Biol (2006) 26:1926.10.1161/01.ATV.0000231512.15115.25
250
NeborDRomanaMSantiagoRVachieryNPicotJBroquereCet alFetal hemoglobin and hydroxycarbamide modulate both plasma concentration and cellular origin of circulating microparticles in sickle cell anemia children. Haematologica (2013) 98(6):862–7.10.3324/haematol.2012.073619
251
WeitzICRazaviPRochandaLZwickerJFurieBManlyDet alEculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation. Thromb Res (2012) 130:361–8.10.1016/j.thromres.2012.04.001
252
DiamantMTushuizenMEAbid-HusseinMNHauCMBoingANSturkAet alSimvastatin-induced endothelial cell detachment and microparticle release are prenylation dependent. Thromb Haemost (2008) 100(3):489–97.10.1160/TH07-12-0760
253
MobarrezFEgbergNAntovicJBroijersenAJorneskogGWallenH. Release of endothelial microparticles in vivo during atorvastatin treatment; a randomized double-blind placebo-controlled study. Thromb Res (2012) 129:95–7.10.1016/j.thromres.2011.09.027
254
TramontanoAFO’LearyJBlackADMuniyappaRCutaiaMVEl-SherifN. Statin decreases endothelial microparticle release from human coronary artery endothelial cells: implication for the Rho-kinase pathway. Biochem Biophys Res Commun (2004) 320:34–8.10.1016/j.bbrc.2004.05.127
255
SuadesRPadroTAlonsoRMataPBadimonL. Lipid-lowering therapy with statins reduces microparticle shedding from endothelium, platelets and inflammatory cells. Thromb Haemost (2013) 110:366–77.10.1160/TH13-03-0238
256
PawelczykMChmielewskiHKaczorowskaBPrzybylaMBajZ. The influence of statin therapy on platelet activity markers in hyperlipidemic patients after ischemic stroke. Arch Med Sci (2015) 11:115–21.10.5114/aoms.2015.49216
257
NomuraSShouzuAOmotoSNishikawaMFukuharaSIwasakaT. Losartan and simvastatin inhibit platelet activation in hypertensive patients. J Thromb Thrombolysis (2004) 18:177–85.10.1007/s11239-005-0343-8
258
TehraniSMobarrezFAntovicASantessonPLinsPEAdamsonUet alAtorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia. Thromb Res (2010) 126:e225–31.10.1016/j.thromres.2010.05.023
259
LinsLCFrancaCNFonsecaFABarbosaSPMatosLNAguirreACet alEffects of Ezetimibe on endothelial progenitor cells and microparticles in high-risk patients. Cell Biochem Biophys (2014) 70(1):687–96.10.1007/s12013-014-9973-9
260
FerreiraCEFrancaCNIzarMCCamargoLMRomanRMFonsecaFA. High-intensity statin monotherapy versus moderate-intensity statin plus ezetimibe therapy: effects on vascular biomarkers. Int J Cardiol (2014) 180:78–9.10.1016/j.ijcard.2014.11.177
261
van DommelenSMVaderPLakhalSKooijmansSAVan SolingeWWWoodMJet alMicrovesicles and exosomes: opportunities for cell-derived membrane vesicles in drug delivery. J Control Release (2011) 161:635–44.10.1016/j.jconrel.2011.11.021
262
TimmersLLimSKArslanFArmstrongJSHoeferIEDoevendansPAet alReduction of myocardial infarct size by human mesenchymal stem cell conditioned medium. Stem Cell Res (2007) 1:129–37.10.1016/j.scr.2008.02.002
263
TimmersLLimSKHoeferIEArslanFLaiRCVan OorschotAAet alHuman mesenchymal stem cell-conditioned medium improves cardiac function following myocardial infarction. Stem Cell Res (2011) 6:206–14.10.1016/j.scr.2011.01.001
264
KervadecABellamyVEl HaraneNArakelianLVanneauxVCacciapuotiIet alCardiovascular progenitor-derived extracellular vesicles recapitulate the beneficial effects of their parent cells in the treatment of chronic heart failure. J Heart Lung Transplant (2016) 35:795–807.10.1016/j.healun.2016.01.013
265
RatajczakMZRatajczakJ. Horizontal transfer of RNA and proteins between cells by extracellular microvesicles: 14 years later. Clin Transl Med (2016) 5:7.10.1186/s40169-016-0087-4
266
GattiSBrunoSDeregibusMCSordiACantaluppiVTettaCet alMicrovesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury. Nephrol Dial Transplant (2011) 26:1474–83.10.1093/ndt/gfr015
267
WangYWeiSWangYLLiuMShangMZhangQet alProtective effects of circulating microvesicles derived from myocardial ischemic rats on apoptosis of cardiomyocytes in myocardial ischemia/reperfusion injury. Oncotarget (2017) 8(33):54572–82.10.18632/oncotarget.17424
268
MalliarasKMakkarRRSmithRRChengKWuEBonowROet alIntracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction). J Am Coll Cardiol (2014) 63:110–22.10.1016/j.jacc.2013.08.724
269
GalletRDawkinsJValleJSimsoloEDe CoutoGMiddletonRet alExosomes secreted by cardiosphere-derived cells reduce scarring, attenuate adverse remodelling, and improve function in acute and chronic porcine myocardial infarction. Eur Heart J (2017) 38:201–11.10.1093/eurheartj/ehw240
270
GettsDRTerryRLGettsMTDeffrasnesCMullerMVan VredenCet alTherapeutic inflammatory monocyte modulation using immune-modifying microparticles. Sci Transl Med (2014) 6:219ra217.10.1126/scitranslmed.3007563
271
WiklanderOPNordinJZO’LoughlinAGustafssonYCorsoGMagerIet alExtracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting. J Extracell Vesicles (2015) 4:26316.10.3402/jev.v4.26316
Summary
Keywords
angiogenesis, atherosclerosis, cardiovascular diseases, cell-derived microvesicles, endothelial dysfunction, inflammation, neovascularization, thrombosis
Citation
Badimon L, Suades R, Arderiu G, Peña E, Chiva-Blanch G and Padró T (2017) Microvesicles in Atherosclerosis and Angiogenesis: From Bench to Bedside and Reverse. Front. Cardiovasc. Med. 4:77. doi: 10.3389/fcvm.2017.00077
Received
22 August 2017
Accepted
22 November 2017
Published
18 December 2017
Volume
4 - 2017
Edited by
Elena Aikawa, Brigham and Women’s Hospital, United States
Reviewed by
Carlos Alonso Escudero, University of the Bío Bío, Chile; Albert Rizvanov, Kazan Federal University, Russia
Updates
Copyright
© 2017 Badimon, Suades, Arderiu, Peña, Chiva-Blanch and Padró.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Lina Badimon, lbadimon@csic-iccc.org
Specialty section: This article was submitted to Atherosclerosis and Vascular Medicine, a section of the journal Frontiers in Cardiovascular Medicine
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.